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Addition of skim milk and non-fat dairy intake to the normal routine diet has been 
demonstrated to reduce blood pressure (BP) and improve vascular function in adults with elevated 
BP.  High consumption of whole milk and full-fat dairy products is accompanied by elevated 
saturated fat intake and an increase in plasma cholesterol concentration.  The solitary effects of 
full-fat dairy products added to the normal diet in adults with elevated BP is not known. Therefore, 
the primary aim of the present study was to determine the efficacy of reducing elevated BP and 
improving vascular function when adding whole milk and full-fat dairy products to the normal 
diet. 
Sixty participants with elevated BP underwent a randomized controlled crossover dietary 
intervention consisting of high dairy and control conditions.  Within the high dairy condition, 
participants underwent an increase in 4 daily servings of whole milk and full-fat dairy products for 
4 weeks in addition to their normal diets.  Dairy consumption was eliminated during the control 
condition for another four weeks while consuming a counterbalanced diet.  A 2-week washout 
period separated the two conditions to remove residual effects from the previous condition.  
In study 1, we sought out to determine the effects of whole milk and full-fat dairy products 
on arterial BP in adults with elevated BP.  We utilized two different but complimentary 
 vii 
assessments incorporating seated and ambulatory BP measurements.  There were no changes in 
systolic or diastolic BP measures for seated BP or ambulatory (e.g. 24-hour, daytime, and night 
time) measures.  In study 2, we studied the effects of added consumption of whole milk and full-
fat dairy to the normal routine diet on vascular function in adults with elevated BP.  No significant 
changes were seen in arterial stiffness, endothelial function, or cardiovagal baroreflex sensitivity.   
Taken together, the findings of this dissertation study demonstrate that unlike skim milk 
and non-fat dairy products, whole milk and full-fat dairy products do not exert hypotensive effects 
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Chapter 1: General Introduction 
Hypertension has been defined as a persistently elevated systolic (SBP) (>140 mmHg) 
and/or diastolic BP (DBP) (>90 mmHg) [1-3].  Approximately 1 in 3 adults over the age of 18 
years are affected by hypertension, representing an estimated 68 million adults within the United 
States [3].  The most common forms of cardiovascular disease (CVD) resulting from sustained 
hypertension include left ventricular hypertrophy and subsequent heart failure, coronary arterial 
disease, and ischemic stroke [4].  Most hypertension cases stem from unknown etiologies, and 
about 70% receive treatment with less than half being controlled [3].  Although the initial events 
leading to hypertension are unclear, vascular dysfunction seems to play a significant role in 
propagating its development.   
Hypertension can be modulated through a variety of behavioral modifications [1, 5-7].  In 
particular, high consumption of non- and low-fat dairy products has emerged as an effective 
strategy against hypertension [5, 8, 9].  We reported that non-fat dairy products not only exerted 
hypotensive effects [10] but also improved key vascular functions related to hypertension [11].  
Reduced central arterial stiffness associated with increased non-fat dairy intake is a critical finding 
as increased arterial stiffness has been viewed as a causal mechanism linked to elevated systolic 
BP as well as an independent contributor to CVD risk [12-14].  
Compared with non-fat dairy products, the effects of consuming high amounts of full-fat 
dairy products are not clear and remain controversial with data demonstrating beneficial effects 
[15, 16] or no effects on BP reduction [17, 18].  Moreover, unlike the traditional notion, recent 
meta-analytical studies have demonstrated that the overall effects of dietary saturated fatty acids 
contained in whole milk and full-fat dairy products are not associated with CVD risks [19, 20].  A 
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recent intervention study modified the original eating plan of the Dietary Approaches to Stop 
Hypertension (DASH) trial by increasing saturated fat content of the diet through replacement of 
non- and low-fat dairy for full-fat dairy products [16].  The higher-fat DASH study revealed similar 
hypotensive effects to the original DASH trial.  However, the study was unable to isolate the effects 
of the full-fat dairy products from other food items responsible for reducing BP (i.e. fruits and 
vegetables).  Currently, no studies have established a causal link of whole milk and full-fat dairy 
products on BP, or vascular function, in adults with elevated BP when added to the normal routine 
diet.   
The overall goal of the study was to determine if whole milk and full-fat dairy products 
exert hypotensive effects as seen with our previous investigation of skim milk and non-fat dairy 
products.  In addition, we evaluated changes in the arterial dynamics corresponding to changes in 
arterial BP through central thoracic arterial stiffness and endothelial function and how such arterial 
dynamics consequentially affected neurogenic factors such as baroreceptor sensitivity. 
PURPOSES AND HYPOTHESES 
Study #1: The aim of study 1 was to determine if a dietary intervention that includes whole milk 
and full-fat dairy products, reduces arterial BP in adults with elevated BP. We hypothesized that 
the solitary addition of conventional whole milk and full-fat dairy products would induce 
significant decreases in seated and ambulatory BP measures in this population.   
 
Study #2: The aim of study 2 was to determine whether the changes in arterial stiffness and/or 
endothelial vasodilatory function were key mechanisms by which dairy products may reduce BP.  
We hypothesized that the hypotensive effects of dairy products would be significantly associated 
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with the corresponding reductions in arterial stiffness and/or increases in endothelial function and 




Chapter 2: Study 1 - Addition of Whole Milk and Full-Fat Dairy Products to 
the Normal Routine Diet on Blood Pressure 
ABSTRACT 
Regular consumption of low- and non-fat dairy products reduces blood pressure (BP) in 
adults with elevated BP. Currently, it is unknown if conventional full-fat dairy products exert 
similar hypotensive effects.  We aimed to determine if adding whole milk and full-fat dairy 
products to the normal routine diet would reduce BP in adults with elevated BP.  Sixty adults 
(mean age±SEM; 58±2 years) with elevated systolic BP (systolic/diastolic BP: 120-159 / <99 
mmHg) were randomized into a controlled crossover intervention trial. The trial consisted of 4 
weeks of high dairy and control conditions separated by a 2-week washout period. The high dairy 
condition consisted of +4 servings/d of conventional full-fat dairy products to the normal routine 
diet, while the control condition (with +4 servings/d of fruit and plant-based products) eliminated 
dairy products from the diet.  Seated systolic BP did not change significantly in either condition. 
When the analyses were divided into subgroups of men and women, there were no changes in 
systolic BP in either sex across either dietary period.  Ambulatory (24-hour) systolic BP did not 
change significantly in the high dairy (133±2 vs. 131±1 mmHg) and control conditions (132±2 vs. 
131±1 mmHg). No significant changes were observed for diastolic BP or pulse pressure during 
either condition for seated and ambulatory measures.  The solitary addition of whole milk and full-
fat dairy products to the normal routine diet does not exert hypotensive effects in adults with 





For most adults living in industrialized societies, systolic blood pressure increases 
progressively throughout the life span [21, 22]. The increases in systolic BP with aging have 
important clinical consequences as elevated systolic BP is one of the major independent risk 
factors for cardiovascular disease (CVD) [23, 24]. To accomplish a reduction in the incidence of 
systolic hypertension, we must identify effective strategies to prevent and treat elevated systolic 
BP in aging adults. Guidelines incorporating lifestyle modifications, including dietary changes, 
are universally the first-line approach used to prevent and treat elevated BP [25].   
Observational studies suggest that high consumption of dairy products is associated with 
reduced risk of hypertension [15, 17, 26, 27]. Indeed, several interventional studies have 
specifically investigated the hypotensive effects of non- and low-fat dairy products on BP [9, 10, 
28]. We have previously demonstrated that the solitary manipulation of conventional non-fat dairy 
added to the normal routine diet reduced both seated and ambulatory (24-hour) systolic BP in 
middle-aged and older adults with elevated BP [10]. Unlike research studies evaluating low and 
non-fat dairy products on BP, the available research studies examining the effect of whole milk 
and full-fat dairy products on BP are extremely limited and are highly controversial with some 
showing no relation [29, 30] while others demonstrating benefits [31] or even increased risk of 
hypertension [17]. Most investigators have attributed the inability of full-fat dairy products to 
modulate BP to milk fat that is rich in saturated fat (>60% of milk fat), which could in turn increase 
low density lipoprotein (LDL) cholesterol and elevate cardiovascular disease risk [32, 33].  
However, the pathogenetic role of saturated fat has become controversial in recent years [20, 34, 
35] as the intake of saturated fat also increases high density lipoprotein (HDL) cholesterol 
 6 
 
offsetting the adverse effects of elevated LDL-cholesterol [36].  Moreover, there are studies 
indicating that milk and milk fat do not adversely affect plasma cholesterol concentrations [16, 
37].  Recently, an abbreviated 3-week DASH study incorporating full-fat dairy products in place 
of low-fat dairy products revealed similar hypotensive effects to the original DASH diet [16].  
However, the study was limited in isolating the effects of the full-fat dairy products thereby 
preventing reduced blood pressure changes to full-fat dairy alone.  
Therefore, the purpose of the present randomized, controlled crossover dietary intervention 
was to determine the effects of adding whole milk and full-fat dairy products to the normal routine 
diet on BP in adults with elevated BP.  We hypothesized that full-fat dairy products would be 
effective in lowering both seated and ambulatory BP.  
METHODS 
Subjects:  A total of 60 subjects who were free of overt chronic diseases participated in 
the present study. During a 2-week run-in period, all eligible subjects went through screening and 
had to demonstrate a consistent resting systolic BP between 120-139 mmHg (prehypertension) or 
140-159 mmHg (stage 1 systolic hypertension) with diastolic BP of less than 99 mmHg on two 
separate occasions during the run-in periods. The BP values were set in accordance with the pre-
existing guidelines of high BP [25]. Exclusionary criteria included overt chronic disease, BMI > 
45 kg/m2, lactose intolerance, high baseline dairy intake (>3 servings/day), pregnancy or lactation, 
strenuous physical activity (>3 times/week), excessive alcohol consumption (>21 drinks/wk), or 
appearance of chronic diseases as assessed during the screening. A data safety monitoring board 
was established to monitor any adverse events. All procedures of the study were reviewed and 
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approved by the University of Texas at Austin’s Institutional Review Board. Written informed 
consent was obtained from all candidates prior to participating in any procedures. 
Experimental Protocol:  With the exception of the dairy and non-dairy food items, the 
study design was identical to our previous study investigating effects of skim milk and non-fat 
dairy products on BP [10]. A randomized, controlled, crossover dietary intervention consisting of 
a 4-week high dairy or no dairy condition was conducted with a minimal 2-week washout period 
between dietary interventions, to remove residual effects associated with the previous intervention. 
The dietary intervention was 4 weeks long as BP changes very rapidly to intervention stimuli as 
early as 2-4 weeks as in our previous dietary intervention study [10].  The random allocation to 
the intervention sequence was conducted by using a coin-flip method. Measurements took place 
at the beginning and end of each dietary intervention period. Due to the nature of the experimental 
dietary conditions, it was not possible to blind subjects or investigators to the dietary condition, 
except during analyses. In the high dairy condition, subjects were asked to consume 4 servings of 
laboratory-provided dairy per day, in addition to their baseline dairy intake.  Subjects could choose 
their 4 dairy servings from any combination of 8 fluid ounces of whole milk (Hill Country Dairies), 
6 ounces of Brown Cow yogurt with cream on top (Stonyfield Farm), and/or 1.5 ounces of Swiss 
cheese (HEB Grocery) in addition to their normal routine diet. In the no dairy (control) condition, 
subjects eliminated all dairy consumption from their routine diet to maximally differentiate dietary 
dairy intake.  In the control condition, subjects consumed 16-fluid ounces of Silk Coconut Milk 
(WhiteWave Services), 16-fluid ounces of HEB branded orange juice fortified with vitamin D and 
calcium (HEB Grocery), 2 ounces of single-serve Plantars salted peanuts (The Kraft Heinz 
Company), and 4-ounce single serve cups of Motts applesauce (Motts LLP) daily to 
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counterbalance total calories from the high dairy condition. All dairy and non-dairy products were 
provided by the investigators in daily packages. The subjects were free to consume the required 
servings spanned throughout the day or all at once. Dietary consultations were completed weekly 
by a licensed dietitian, with the exception of the 2-week washout period required to remove 
residual effects from the previous condition [10, 16].  Consultations involved dietary protocol 
instruction, compliance monitoring, and adjustment of caloric intake based on significant changes 
in body weight (±2 kg).   
Measurements were taken at the beginning and end of each dietary condition at the same 
time of day to eliminate any diurnal effects.  Subjects were asked to avoid exercise, caffeine 
consumption, and fast 12 hours prior to measurement.  Premenopausal women were tested during 
self-reported early follicular phase of the menstrual cycle in both dietary conditions of the study.  
Throughout the entire experimental protocol, subjects were instructed to maintain their normal 
lifestyle (e.g., physical activity) aside from dietary changes prescribed by the dietitian.     
Statistical Analysis:  A priori testing for statistical power of 80% and sample size 
calculations were performed using nQuery Adviser computer software (Statistical Solutions, 
Boston, MA). Sample size calculations were based on estimated effect sizes for the dependent 
variables of previous lifestyle modification studies in adults [10, 38-40]. All statistical analyses 
were conducted using SPSS 23.0 statistical software (Chicago, IL). To test the effectiveness of the 
washout period, a 2-factor (sequence x visit) mixed-model repeated measures ANOVA was 
utilized.  Prior to any statistical testing, assumptions of normality and variance were determined 
through each condition by utilizing the Shapiro-Wilk and Levene’s test, respectively. To control 
random effects occurring due to condition and major dependent variables, mixed-effect modelling 
 9 
 
was used to assess statistical significance. A 2-factor mixed-model ANOVA with repeated 
measures was used to evaluate differences between each dietary condition (condition x time) for 
subject characteristics, dietary changes, and BP measures. A 3-factor mixed-model ANOVA with 
repeated measures was also utilized to evaluate sex/gender differences (sex x condition x time) on 
BP measures. Further subgroup analyses were conducted to assess whether age and menopausal 
status could influence the outcome. Partial correlation analyses were conducted to detect 
associations attributed to separate dairy elements while controlling for the other dairy products 
given to participants. To follow significant interactions, post-hoc tests were performed using the 
Bonferroni Procedure. Per-protocol analysis was implemented for all subjects that have fully 
complied with the study [10]. The alpha value was set at P<0.05 for all analyses.  Data are 
presented as means±SEM. 
Detailed Methods: 
Seated resting brachial BP  
BP recordings were made under quiet, comfortable ambient (~24ºC) laboratory conditions. 
To avoid any possibility of investigator bias, measurements were made with a semi-automated 
device (HEM-907XL; Omron Healthcare, Vernon Hills, IL), which uses an oscillometric 
technique over the brachial artery of the right arm. Recordings were made in triplicate in the seated 
position. All measurements conformed strictly to the American Heart Association guidelines [41].     
24-hour ambulatory BP  
BP was recorded over a 24-hour period of normal daily activity utilizing a noninvasive 
ambulatory monitor (Model 90217; Spacelabs Healthcare, Snoqualmie, WA). The cuff was 
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programmed to inflate automatically every 15 minutes from 6:00 AM to 11:00 PM and every 20 
minutes between 11:00 PM and 6:00 AM [10].   
Blood Samples 
Whole blood was collected by venous puncture. All plasma samples were centrifuged, 
decanted, and stored at -80ºC for future assay. Commercially available kits using enzymatic 
methods were used to determine whole blood concentrations of glucose, total cholesterol, LDL-
cholesterol, HDL-cholesterol, triglycerides, and glycated hemoglobin (DCA Systems; Siemens 
Healthcare Diagnostics, Los Angeles, CA). Quantification of plasma concentration of insulin were 
determined through enzyme-linked immunosorbent assays (Mercodia, Winston Salem, NC).  
Fasting concentrations of blood glucose and insulin were used to assess changes in insulin 
resistance utilizing homeostatic model assessment of insulin resistance (HOMA-IR) [42]. 
Dietary analyses 
Under the supervision of a licensed dietitian, self-administered 3-day dietary recall forms 
were used to capture the subjects’ diet at baseline and during the study conditions.  A 3-day dietary 
recall form was also collected during the washout period. Dietary composition and caloric intake 
were analyzed using Nutritionist Pro software (Axxya Systems, Stafford, TX). Compliance was 
monitored through laboratory provided, self-administered compliance logs. 
RESULTS 
A total of 28 males and 32 females completed the study (Table 2.1). No adverse events 
were reported throughout the study period. There were no carryover effects during the 2-week 
washout period.  Subject compliance for consuming laboratory-provided food items were 94% and 
96% in the control and high dairy conditions. No changes in body weight or BMI were observed 
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throughout the duration of the study. There were slight but significant increases in total cholesterol 
concentrations during the high dairy condition (P < 0.05) but no changes were observed during the 
control condition. LDL-cholesterol was the main contributor to total cholesterol despite a lack of 
significance (P = 0.074) as HDL-cholesterol and triglycerides did not change. Blood glucose was 
also slightly elevated during the high dairy condition (P < 0.05).  HOMA-IR did not change 
significantly and did not differ between the two dietary conditions. 
There were no significant changes in total caloric intake after either condition (Table 2.2). 
In the high dairy condition, total dairy intake increased to 4.4±0.2 servings/day while it decreased 
to 0.0±0.1 servings/day in the control condition.  As expected, dietary saturated fat and protein 
intake increased during the high dairy condition (P < 0.001 for both). Total carbohydrate intake 
was greater in the control than the high dairy condition (P = 0.001). There were significant 
reductions in sodium intake as a main effect of time (P < 0.05) but the interaction was not 
significant.  There were no significant differences in sodium intake between the study conditions.  
Seated BP data are presented in Figure 2.2. Seated systolic BP, diastolic BP, and pulse 
pressure did not change significantly in either condition. Despite no interaction effect, a main effect 
of time was present for the seated systolic BP (P < 0.03) (Figure 2.3) suggesting equivalent 
reductions in systolic BP for both control and high dairy conditions.  No association in seated 
systolic or diastolic BP was found for whole milk (controlling for yogurt and cheese intake), yogurt 
(controlling for whole milk and cheese intake), or cheese (controlling for whole milk and yogurt 
intake). 
Subgroup analyses revealed no changes in seated or ambulatory systolic and diastolic BP 
for men or women.  When female subjects were divided into pre- and post-menopausal women, 
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premenopausal women did not exhibit different BP during baseline for seated or ambulatory 
measures from postmenopausal females and demonstrated no differential effects on any blood 
pressure with respect to dietary condition.  With respect to age, no condition or time effect was 
found.  However, as expected, the main effect of age did demonstrate significantly higher systolic 
BP values for both seated and ambulatory systolic BP values.    
Ambulatory BP data are displayed in Figure 2.4.  No significant changes in 24-hr systolic 
BP were observed in the control and high dairy conditions. The results were the same when the 
data were divided into daytime and nighttime systolic BP.  Similarly, there were no significant 
changes in ambulatory diastolic BP or pulse pressure for 24-h, daytime, and night in either 
condition. When the data were stratified for sex, there were no significant differences in 24-hour, 
daytime, and night BP in either of the dietary interventions in both males and females.  24-hour 
and daytime ambulatory systolic BP were reduced to a similar extent over time (P < 0.05) (Figure 
2.5).  No partial correlations in 24-hour, daytime, or night time ambulatory systolic or diastolic BP 
were found for whole milk (controlling for yogurt and cheese intake), yogurt (controlling for whole 




Table 2.1 Overall changes in selected subject characteristics and blood chemistry with no dairy 
and high dairy conditions. 
All values are means±SEMs. BMI=Body Mass Index, HDL=High Density Lipoprotein, 
LDL=Low Density Lipoprotein, HOMA=Homeostasic Model Assessment. All significant 
variables were preceded by a significant interaction effect (time x condition). *P < 0.05 vs Before; 
†P < 0.05 vs After in the No Dairy condition. 
  
 No Dairy High Dairy 
Variables Before After Before After 
Age (years) 58±2 - 58±2 - 
Height (cm) 168±1 - 168±1 - 
Body mass (kg) 85±2 85±2 84±2 85±2 
BMI (kg/m2) 29.2±0.8 29.3±0.8 29.1±0.8 29.2±0.8 
Total cholesterol (mmol/L) 5.1±0.1 5.0±0.1 5.0±0.1 5.3±0.1*,† 
HDL cholesterol (mmol/L) 1.30±0.07 1.26±0.06 1.32±0.06 1.31±0.06 
LDL cholesterol (mmol/L) 3.04±0.12 3.02±0.12 3.02±0.12 3.28±0.12 
Triglycerides (mmol/L) 1.46±0.12 1.41±0.12 1.41±0.12 1.42±0.12 
Blood glucose (mmol/L) 5.29±0.10 5.27±0.10 5.27±0.10 5.46±0.10*,† 
Glycated hemoglobin (%) 5.6±0.04 5.5±0.05 5.5±0.04 5.5±0.05 
Insulin (pmol/L) 66±6 63±4 66±6 64±4 
HOMA-IR 1.25±0.12 1.19±0.08 1.24±0.12 1.22±0.08 
 14 
 
Table 2.2 Overall changes in dietary intake with no dairy and high dairy conditions. 
All values are means±SEMs. All significant variables were preceded by a significant interaction 
effect (time x condition). *P < 0.05 vs Before; †P < 0.05 vs After in the No Dairy condition  
 No Dairy High Dairy 
Variables Before After Before After 
Calories (kcal/d) 1996±68 2061±60 1965±68 2106±58 
Total Fat (g/d) 83±4 89±3 85±4 96±3 
Saturated Fat (g/d) 27±1 28±1 27±1 39±1*,† 
Monounsaturated Fat (g/d) 19±1 25±1*,† 20±1 20±1 
Polyunsaturated Fat (g/d) 11±1 8±1*,† 10±1 10±1 
Carbohydrate (g/d) 222±9 233±8 220±9 213±8† 
Protein (g/d) 77±3 74±4 77±3 94±4*,† 
Alcohol (g/d) 5±1 3±1 3±1 3±1 
Sodium (mg/d) 3043±149 2558±160 3123±148 2820±157 
Potassium (mg/d) 1901±106 2651±104* 1975±106 2226±102*,† 
Calcium (mg/d) 892±56 1914±71* 817±56 1513±71*,† 
Magnesium (mg/d) 210±14 209±14 210±13 214±13 
Vitamin D (IU/d) 360±113 659±115* 369±112 449±115† 























Figure 2.1 Participant flow chart through the dietary intervention trial. 
  
671 Candidates contacted  
485 Excluded: 
     241 Ineligible after prescreen 
     244 Declined to participate 
  
186 Assessed by screening 
  
90 Eligible candidates proceeded to 
randomization 
  
24 Withdrew prior to start 
  
32 Randomly assigned to no dairy 
condition first 
  
34 Randomly assigned to high 
dairy condition first 
  


















60 Completed study and 




     76 Ineligible after 1st screen 





Figure 2.2 Seated brachial systolic (A) and diastolic (B) BP before and after no dairy and high 





Figure 2.3 Main effect of time on seated brachial systolic BP. *Denotes significant main effect of 






Figure 2.4 Ambulatory (24-hour), daytime, and night time systolic and diastolic BP before and 






Figure 2.5 Main effects of time for ambulatory (24-hour), daytime, and night time BP. *Denotes 








The present study was the first to investigate the effects of conventional full-fat dairy 
products on seated and ambulatory BP in adults with elevated BP. We found that whole milk and 
full-fat dairy products did not lower BP significantly when consumed in addition to the normal 
routine diet. The results were consistent for both seated and ambulatory BP measures.  These 
results suggest that unlike the hypotensive effects of skim milk and non-fat dairy products 
observed in our previous study [10], the solitary manipulation of conventional full-fat dairy 
products was not effective in reducing BP in adults with elevated BP.     
We have previously demonstrated that solitary addition of skim milk and conventional non-
fat dairy products to the routine diet reduced BP in middle-aged and older adults with elevated BP 
[10].  In the present study, we used the same interventional design, similar experimental protocol, 
and identical dependent measures that were successfully implemented in our previous study.  
However, the results of the present study were in marked contrast to the our previous investigation 
as the hypotensive effects of dairy products were not replicated with whole milk and conventional 
full-fat dairy products [10]. Only one other dietary intervention study has investigated the effect 
of full-fat dairy products on BP in humans when added to the normal diet [43]. A major limitation 
of that study was that the research subjects were young, healthy normotensive college students that 
had very low (i.e., normal) BP prior to the dietary interventions.  In fact, BP was not reduced 
during the low-fat dairy condition, and the high-fat dairy condition increased BP significantly.  
The results of the present intervention study are consistent with some of the observational studies 
reporting no differences in BP between adults who consume high-fat dairy products and those who 
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do not (13-15).  Taken together, these findings suggest that the regular intake of whole milk and 
full-fat dairy products added to the normal routine diet are not associated with reduced BP.          
Similar to non- and low-fat dairy products, whole milk and full-fat dairy products contain 
similar or even greater amounts of constituents that have been implicated in the hypotensive 
effects.  Lactotripeptides (LTPs), found in fermented dairy products, can exert BP-lowering effects 
that resemble ACE inhibitors [10, 38-40].  In addition, dairy proteins may also contribute to its 
hypotensive effects [44].  The hypotensive properties of dairy products have also been ascribed to 
micronutrients including potassium, calcium, and vitamin D [30, 45, 46].  These bioactive peptides 
are present in both whole milk and full-fat dairy products as in skim milk and non-fat dairy 
products.  What then are the potential mechanisms underlying reduced BP that were not observed 
in the dietary intervention incorporating whole milk and full-fat dairy products?  The lack of 
significant BP reduction in this study may be attributed to a greater amount of milk fat that is rich 
in saturated fat leading to vascular dysfunction and the interference with the hypotensive effects.  
Animal studies have demonstrated that high consumption of saturated fats results in the elevation 
of arterial BP [32, 33], presumably mediated through insulin resistance and/or oxidative stress 
[47].  The heightened inflammatory and oxidative response also promotes the renin angiotensin 
system (RAS) to produce angiotensin II (AngII) exerting chronic vasoconstrictive restraint on the 
arterial wall [48].  Clearly, further studies are needed to determine how constituents in full-fat 
dairy products, particularly saturated fat, interfere with the BP lowering effects. 
Both pre and post measures of saturated fat consumption were lower in our previous 
investigation of non-fat dairy products [10] than in the current investigation.  As carbohydrate and 
protein consumption were similar between the non-fat dairy study [10] and the current study, 
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elevated saturated fat intake may be a primary suspect for increased caloric content.  Interestingly, 
monounsaturated fat content was significantly increased during the control condition while 
polyunsaturated fats were decreased.  Increased consumption of monounsaturated fats by 8% of 
calories is enough to significantly reduce BP by approximately 9 mmHg in adults with elevated 
BP when saturated fat content was set to 6% of calories [49].  In the current study, 
monounsaturated fats were increased during the control while saturated fat content was 
maintained.  Both protein and saturated fat content increased during the high dairy condition.  The 
monounsaturated fat and protein content of the control and high dairy condition, respectively, may 
exert hypotensive effects, thereby explaining a potential time effect for seated and ambulatory 
systolic BP.  However, the investigators were limited by nutritional labelling whereby food 
manufacturers are not required to disclose mono- and polyunsaturated fat content [50] leading to 
estimations derived from the USDA nutrient profile data bank [51].  Interestingly, several other 
studies examining the effects of engineered full-fat dairy products, incorporating elevated mono- 
and polyunsaturated fats based on altering bovine feed, have demonstrated reduced total and LDL-
cholesterol [52-55].  Unfortunately, no studies have yet examined the implications surrounding BP 
in adults with elevated BP consuming mono- and polyunsaturated-enriched dairy-based products.  
Overall, our findings suggest that protein, and other dairy constituents within generic full-fat dairy 
products, were unable to overcome the negative effects of saturated fat. 
Non- and low-fat dairy products have been widely recommended for the prevention of 
hypertension and CVD.  However, a concern has been raised that full-fat dairy products may 
increase the risk of hypertension and CVD due to a high-fat content in dairy products.  Indeed, 
increases in systolic BP have been reported with the consumption of saturated fats in experimental 
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studies [56, 57]. In the present study, total cholesterol concentration increased significantly in the 
high dairy condition.  However, the duration of the present dietary interventions was relatively 
brief by design as BP responds robustly to dietary changes.  It is not known if longer-term 
consumption of high-fat dairy products raises plasma cholesterol and BP thereby elevating the 
risks of CVD.      
A major strength of the present study is the solitary addition of whole milk and full-fat 
dairy products to the normal routine diet.  We reason that such conventional approach would be 
more applicable to the general population.  A major limitation of the study may be varying degree 
of differences in macro- and micronutrients between the high dairy and non-dairy conditions. 
There were no differences in total calories, total fat, and sodium intake but carbohydrate, protein, 
and potassium intake were different between the dietary conditions.  The no-dairy condition was 
created to be closely matched to the high dairy condition in terms of calories (e.g., whole milk vs. 
coconut milk).  It should be noted that the primary intent of the control condition was to 
demonstrate that dependent measures (i.e. seated and ambulatory BP) would remain stable during 
the control condition.  Another major limitation of the study was the different treatment for 
subgroup of subjects. Though premenopausal females were expected to get their baseline measures 
during their early follicular phase, the investigators did not validate the claims made by the 
participants.  Some might further argue that subjects being non-compliant with the diet might 
confirm lack of significant findings.  However, one could argue that the consumption of whole 
milk and full-fat dairy products from participants may be validated by increases in total cholesterol 
and blood glucose concentrations that would be expected with increases in saturated fat content, 
thereby validating.  
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Rising blood glucose and total cholesterol levels are to be expected with increasing 
saturated fat intake.  In animal models, short-term responses to saturated fat intake have 
demonstrated reduced glucose clearance [47, 58]. Over a 24-hour period, saturated, 
monounsaturated, and polyunsaturated fats decrease glucose clearance by impairing insulin 
secretion and with saturated fat decreasing insulin sensitivity in overweight and obese non-diabetic 
humans [59].  In lean healthy volunteers, an increase in saturated fat consumption over a 4-week 
period did not induce changes in insulin resistance [60].  In contrast, a 3-month isoenergetic diet 
demonstrated reduced insulin resistance [61] when compared with a diets rich in monounsaturated 
fats.  Therefore, it appears that elevated saturated fat consumption may exert greater effects over 
time in lean individuals.  Within the current study, we did not observe increases in insulin 
resistance over a 4-week span based on HOMA calculations, but it may be likely that our dietary 
intervention might be too short.  With respect to dairy protein, whey is effective in reducing insulin 
resistance in overweight and obese individuals over the span of 6 and 12 weeks [62].  Therefore, 
the dairy protein may offset the negative cardiometabolic effects of the saturated fats, but such 
effect may be dependent upon the adiposity of the individuals.  One trend that is clear is that an 
increase in total cholesterol was seen in both shorter and longer-term studies with increase 
saturated fat intake with lean individuals [60, 61] thereby increasing CVD risk.  
 Further subgroup analyses did not provide any new further insights in the present study.  
In our first analysis, BP differences between males and females were assessed.  When compared 
to males, females generally demonstrate a pronounced systolic BP at the seventh decade of life, as 
BP in males is typically higher until the sixth decade [21, 63].  However, sex differences were not 
seen in our study.  A lack of sex differences was also demonstrated in our previous investigation 
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examining non-fat dairy products [10].  Studies demonstrating reduced BP with estrogen therapy 
in post-menopausal women suggest lack of estrogen is responsible for increasing BP in post-
menopause [64, 65].  To further investigate potential impacts of estrogen, we assessed baseline 
and post-test BP measures between pre- and post-menopausal females.  However, no significant 
differences were observed.  Overall main effects of age were seen for both sexes with respect to 
elevated diastolic BP in the older (i.e. 6th and 7th decades) compared with the younger age groups 
(i.e. 2nd, 4th, and 5th decades).  Yet, such differences between age groups are to be expected as there 
is a decrease in diastolic BP after the 5th decade of life [22]. 
Several unanswered questions have risen regarding the hypotensive properties of full-fat 
dairy products. What is the physiological mechanism as to how full-fat dairy products interfere 
with hypotensive effects of dairy products?  Could elevated BP be attenuated when saturated fat 
in dairy is replaced with mono- and polyunsaturated fats?  Could the increase in total cholesterol 
and glucose concentrations exert potential hypertensive effects if the duration of the dietary 
intervention was prolonged for 8-12 weeks? 
In conclusion, the present dietary intervention study demonstrated that the incorporation of 
whole milk and full-fat dairy products into the normal routine diet did not reduce BP on adults 
with elevated BP.  The present findings are in marked contrast to the dietary intervention study 
that we conducted using skim milk and non-fat dairy products with very similar experimental 
conditions.  These findings are not consistent with the recommendations that all dairy products are 




Chapter 3: Study 1 - Effects of Whole Milk and Full-Fat Dairy Products on 
Subclinical Vascular Function in Adults with Elevated Blood Pressure 
ABSTRACT 
High consumption of low- and non-fat dairy products improves vascular dysfunction 
associated with elevated arterial blood pressure (BP).  Currently, it is unknown if conventional 
full-fat dairy products mediate similar vascular responses.  To determine if adding whole milk and 
full-fat dairy products to the normal routine diet improves vascular function in adults with elevated 
BP.  Sixty adults (age±SEM; 58±2 years) with elevated blood pressure (systolic/diastolic; 120-
159/<99 mmHg) were randomized into a controlled crossover intervention trial consisting of two 
4-week dietary periods.  The high dairy condition consisted of adding 4 daily servings of whole 
milk or full-fat dairy products to the normal diet and eliminated all dairy intake during the 
alternative condition.  A 2-week washout period separated the dietary conditions.  Carotid-femoral 
pulse wave velocity (cfPWV) did not change significantly in the high dairy (11.3±0.3 vs. 10.9±0.3 
m/sec) and control conditions (11.2±0.3 vs. 11.0±0.3 m/sec).  The results were consistent when 
ultrasound-derived vascular distension measures (arterial compliance, beta-stiffness index, and 
elastic modulus) were evaluated.  Cardiovagal baroreceptor sensitivity (via Valsalva maneuver) 
demonstrated no significant change for either dietary condition.  Brachial arterial flow-mediated 
dilation (FMD), a measure of endothelium-dependent vasodilation, did not change significantly 
during the high dairy (5.7±0.5 vs. 5.4±0.6%) and control conditions (6.5±0.5 vs. 5.6±0.6%).  The 
solitary addition of whole milk and full-fat dairy products has no effect on subclinical vascular 




The vasculature can be compartmentalized into a compliance function in the large elastic 
arteries and a conduit function residing in more downstream arteries.  Accordingly, the 
elasticity/stiffness and the contractile state of the arterial wall are the primary components that 
determine vascular function.  Inability of the vasculature to change its geometry in response to 
various stimuli (e.g., pulsatile flow, shear stress) is an indicator of declining arterial function.  Age-
associated increases in arterial stiffness contribute to the rise in arterial systolic blood pressure 
(BP) and overall cardiovascular disease (CVD) risk [12, 66].  Arterial stiffening, in turn, blunts 
the sensitivity of baroreceptors and attenuates beat-by-beat mechanisms for regulating arterial BP 
[38, 67, 68].  Additionally, the degree of endothelial dysfunction is closely associated with the 
severity of hypertension [69] although whether endothelial dysfunction initiates hypertension, or 
exists as a consequence thereof, remains highly controversial [70].  Therefore, strategies to 
improve vascular function should lead to better BP control and reduced CVD risks.   
Dietary behavior is known to modulate vascular function associated with reduced arterial 
BP [71, 72].  In particular, regular dairy intake has been associated with reduced arterial stiffness 
and improved endothelial function [11, 71, 73].  Dietary interventional studies have documented 
that non- and low-fat dairy products would lead to improvements in subclinical vascular functions 
[11, 71, 74].  We have previously reported reduced arterial stiffness, increased endothelial 
function, and enhanced cardiovagal baroreflex sensitivity following the solitary addition of skim 
milk and non-fat dairy products to the normal routine diet [11].  However, whether whole milk 
and full-fat dairy products could exert similar effects on vascular function remain unclear.  Due to 
the negative implications surrounding saturated fat contained in full-fat dairy products, some have 
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called for the replacement of full-fat with lower dairy fat alternatives.  However, elevations in 
CVD-risk with saturated fat intake have not been supported by recent studies [20, 34, 35].  More 
importantly, no dietary interventional study has assessed the effects of adding whole milk and full-
fat dairy products to the normal routine diet on vascular function.   
Accordingly, the primary aim of the present study was to determine the effects of whole 
milk and full-fat dairy products on vascular function when added to the normal routine diet in 
adults with elevated BP.  We hypothesized that dietary intervention consisting of full-fat dairy 
products would result in improved vascular function as determined by arterial stiffness, endothelial 
function, and cardiovagal baroreflex sensitivity. 
METHODS 
Subjects:  A total of 60 adults (53% female) with elevated BP (137±1/83±1 mmHg) 
completed the study.  Exclusion criteria were: overt chronic diseases, pregnancy or lactation, 
smoking, type I or II diabetes, milk allergy or lactose intolerance, high baseline dairy intake (>3 
servings/d), BMI >45 kg/m2, or strenuous physical activity (>3 times/wk).  All eligible participants 
were screened during a 2-week run-in period to ensure a consistently elevated systolic BP at rest 
of 120-159 mmHg and diastolic BP of <99 mmHg on two separate occasions [25].  Prior to the 
participation, informed consent was obtained from all subjects in accordance with the University 
of Texas at Austin’s Institutional Review Board. 
Experimental Design:  As depicted in Figure 3.1, participants were randomized into a 
high dairy or no dairy (control) condition for the first 4 weeks and performed the alternative 
condition for the final four weeks with a minimal 2-week washout period.  For premenopausal 
women, a 4-week washout period was used to ensure that baseline measures were started in the 
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same early follicular phase for both dietary conditions.  During the high dairy condition, subjects 
chose their 4 daily servings from a list of dairy items provided by investigators: 8 fluid ounces of 
generic Hill Country whole milk (Hill Country Dairies, Austin, TX), 6 ounces of single-serve 
container of Brown Cow yogurt with cream on top (Stonyfield Farm, Londonderry, NH) and 1.5 
ounces of HEB branded Swiss cheese (HEB Grocers, San Antonio, TX).  During the no-dairy 
condition, an isocaloric plant-based control for the dairy products were provided by investigators: 
16 fluid ounces of HEB branded orange juice fortified with vitamin D and calcium (HEB Grocers, 
San Antonio, TX), 16 fluid ounces of Silk coconut milk (WhiteWave Services, Inc., Broomfield, 
CO), 2 ounces of Plantar salted peanuts (Kraft Heinz Company, Glenview, IL), and 4 ounces of 
Motts applesauce (Motts LLP, Plano, TX).  In the control condition, subjects eliminated all the 
dairy consumptions from their diet in order to maximize the differential dairy intake between the 
two dietary conditions.  All the dairy products were provided in daily packages by the 
investigators.  Milk was provided by the gallon with measuring cups.  Yogurt and cheese products 
were in single-serve packaging.  The subjects were free to consume the required servings at any 
time of day as a single dose or all at once.  Throughout the entire experimental period, the subjects 
were instructed to maintain their body weight, physical activity, as well as their usual diet other 
than those prescribed by the dietitian.  All subjects met weekly with a licensed dietitian to measure 
body weight, receive weekly dietary food items, and ensure compliance.  All measurements were 
taken before and after the dietary protocol following a 12-hour overnight fast (e.g., no caffeine, 
alcohol, food, or exercise). 
Statistical Analyses:  A priori testing was performed to determine sample size based on 
the effect size of previous interventional studies on similar vascular outcome measures (nQuery 
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Advisor, Statsols, Boston, MA) [11, 39, 40].  To control for random effects, two-factor (condition 
x time) mixed-model ANOVA with repeated measures were used assessed all subject 
characteristics and main dependent variables. Because there were no sex/gender-related 
differences, sex was dropped from one of the factors.  To identify significant interactions, Tukey’s 
Least Significant Difference (LSD) post hoc tests were performed.  Pearson correlation 
coefficients were calculated for additional subgroup analysis. Partial correlation was utilized to 
assess associations in individual dairy elements while controlling for the other dairy products in 
the study for the main dependent variables. All statistical analyses were performed using SPSS 
23.0 statistical software (SPSS, Inc., Chicago, IL).  The alpha value was set at P<0.05 for all 
analyses.  Data were presented as means±SEM. 
Detailed Methods: 
Blood Samples   
All blood samples were taken from the antecubital fossa by venous acupuncture by a 
certified phlebotomist.  Whole blood samples were collected, centrifuged, then the plasma was 
aliquoted and stored at -80ºC for future analyses.  Plasma concentrations of endothelin-1 (R&D 
Systems, Minneapolis, MN), total nitric oxide (NOx) consisted of nitrite/nitrate (ENZO Life 
Sciences, Farmingdale, NY), and epinephrine/norepinephrine (Abnova, Taipei City, Taiwan) were 
determined via enzyme-linked immunosorbent assays to evaluate changes in circulating vasoactive 
factors in response to dietary interventions.   
Pulse Wave Velocity and Blood Pressure  
Participants were required to get their seated blood pressure readings weekly when they 
came in to receive their weekly portion of food.  Measurements were taken in triplicate by an 
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automated device (HEM-907XL; Omron Healthcare, Vernon Hills, IL) in a dimly lit room.  All 
blood pressure measurements were in accordance with the American Heart Association guidelines 
[41].  Supine brachial blood pressure was measured with the participants in the supine position 
using oscillometric automated sphygmomanometer (VP-1000 Plus, Omron Healthcare, Kyoto, 
Japan) to assess brachial-ankle index during the pre and post testing visits. Carotid-femoral pulse 
wave velocity, an index of arterial stiffness, and carotid artery pressure waveforms were obtained 
using an automatic vascular screening device (VP-1000 Plus, Omron Healthcare, Kyoto, Japan) as 
previously described [11]. 
Carotid Artery Compliance 
The combination of ultrasound imaging of a common carotid with simultaneous 
tonometric-obtained arterial pressure waveforms from the contralateral artery permitted 
noninvasive determination of carotid artery compliance [75]. Arterial diameter was measured from 
the images derived from an ultrasound machine (iE33 Ultrasound System, Phillips, Bothel, WA) 
equipped with a high-resolution linear-array transducer as previously described [75].  A 
longitudinal image of the cephalic portion of the common carotid artery was acquired 1-2 cm 
proximal to the carotid bulb with the transducer placed at 90 degrees to the vessel.  All image 
acquisitions were performed in duplicate, for data quality assurance, by a trained technician.  All 
ultrasound-derived diameter data was analyzed utilizing automated image analysis software 
(Carotid Analyzer, Medical Imaging Applications, Coralville, IA) by the same investigator who 
was blinded to the dietary conditions.  Arterial pressure waveforms were obtained using the arterial 
tonometry placed on the carotid artery and recorded on a data acquisition software (Windaq 2000, 
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Dataq Instruments, Akron, OH).  Intima-media thickness was measured at end diastole as 
previously described [76]. 
To ensure comprehensibility, we characterized arterial mechanical properties of the carotid 
artery through several measures including compliance, arterial distension, elastic modulus, and 
beta-stiffness index.  Arterial compliance is a measure of absolute change of cross-sectional area 
following blood pressure changes whereas arterial distension is a relative change of cross-sectional 
area following blood pressure changes [77, 78].  Beta-stiffness index controls for distension 
pressures brought about by changes in blood pressure [79].  Elastic modulus is a theoretical 
measure assessing the amount of pressure needed for a 100% stretch of the arterial wall [77]. 
Flow-Mediated Dilatation (FMD) 
FMD is a non-invasive method to assess vascular endothelium-derived vasodilatory 
function as previously described [80, 81].  Brachial artery diameters and blood flow velocity was 
measured with an ultrasound machine equipped with a high-resolution linear array transducer 
(Phillips iE33 Ultrasound System, Bothel, WA).  A longitudinal image of the brachial artery was 
acquired 5-10 cm proximal to the antecubital fossa.  A BP cuff was placed on the forearm 3-5 cm 
distal to the antecubital fossa and inflated to 100 mmHg above resting systolic BP for 5 minutes 
using a rapid cuff inflator (E20, D.E. Hoakanson, Bellvue, WA).  After cuff deflation, brachial 
artery diameters and blood velocity were measured for 3 minutes.  All ultrasound-derived diameter 
data were analyzed by the same investigator who was blinded to dietary conditions, using 
automated image analysis software (Brachial Analyzer, Medical Imaging Applications, Coralville, 




Cardiovagal Baroreflex Sensitivity (BRS)   
Cardiovagal BRS was determined using Valsava maneuver technique as previously 
described [82].  After deep inspiration, subject performed forced expiration though a mouthpiece 
with 1-inch diameter.  An expiratory mouth pressure was maintained at 40 mmHg for 10 seconds 
using visual feedback (Windaq, Dataq Instruments).  Measurements of R-R interval (ECG) and 
beat-to-beat arterial blood pressure (Portapres, Ohmeda) were collected throughout the testing 
period.  Cardiovagal BRS was analyzed using the phase IV of the Valsalva maneuver.  The R-R 
interval was regressed on the systolic blood pressure, the slope of this relation (ms/mmHg) 
represented the cardiovagal BRS if the linear regression coefficient (r) greater than 0.80. 
RESULTS 
 Participants maintained body mass throughout the duration of the study.  Dropout rate from 
the study after randomization and completing the first baseline visit was 10%.  Overall, no sex-
related differences between dietary conditions were found for any dependent variable.  When 
females were divided into pre- and post-menopause, postmenopausal females exhibited greater 
central arterial stiffness than premenopausal females (P<0.05) despite no effects from time or 
treatment effects.  Furthermore, BP medication had no impact on the dietary intervention. 
During the intervention, total dairy intake was reduced from baseline to post testing visits 
during the control condition (0.7 ± 0.2 vs. 0.0 ± 0.1 servings/d; P < 0.05) and increased during the 
high dairy condition (1.5 ± 0.2 vs. 4.6 ± 0.1 servings/d; P < 0.05).  The rise in dairy intake during 
the high dairy condition was significantly greater than during the control condition (P < 0.05).  An 
in-depth analysis corresponding to macro- and micronutrient profiles for each of the dietary 
interventions has been published elsewhere. 
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Arterial stiffness parameters including brachial-ankle PWV and carotid augmentation 
index (Table 3.2) exhibited no changes.  Central arterial distensibility measures encompassing 
carotid arterial compliance, distensibility, and elastic modulus remained consistent throughout the 
duration of the study. Interestingly, an interaction effect was seen approaching significant levels 
for beta stiffness index (P = 0.052), demonstrating elevated stiffness after the high dairy condition 
when compared to the control condition with respect to pairwise post hoc comparisons (P = 0.049).  
Central arterial stiffness did not exhibit changes between the dietary conditions (Figure 3.2A) as 
measured by cfPWV but did demonstrate significant reductions as a main effect of time (P = 0.004) 
(Figure 3.3). When divided by decade of age, a main effect of age was also present for cfPWV (P 
< 0.001).  In addition, a positive relationship was demonstrated between cfPWV and age (r = 0.46; 
P < 0.001).  Partial correlation did not reveal any associations between cfPWV and whole milk 
(controlling for yogurt and cheese intake), yogurt (controlling for whole milk and cheese intake), 
or cheese (controlling for whole milk and yogurt intake). Due to the poor quality of data, few 
participants were eliminated from analysis of the ultrasound-derived distensibility measures 
including arterial compliance, distension, beta-stiffness, and elastic modulus (total analyzed; 
n=58) and the arterial stiffness measure cfPWV (total analyzed; n=55). 
As depicted in Figure 2.2B, endothelial function, as measured through FMD, did not 
change across both dietary conditions.  Partial correlation between FMD and whole milk 
(controlling for yogurt and cheese intake), yogurt (controlling for whole milk and cheese intake), 
or cheese (controlling for whole milk and yogurt intake). In addition, consistent with the findings 
of central arterial stiffness and endothelial function, BRS also remained unchanged throughout the 
duration of the study (Table 3.2).  However, a main effect of age was present for BRS (P < 0.001).  
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An inverse trend was also noted between age and BRS (r = 0.35; P < 0.001). Surprisingly, partial 
correlations revealed negative association between BRS and whole milk (controlling for yogurt 
and cheese intake)(r = -0.30; P < 0.05), yogurt (controlling for whole milk and cheese intake)(r = 
-0.29; P < 0.05), and cheese approaching significance (controlling for whole milk and yogurt 
intake)(r = -0.26; P = 0.056). Endothelial-derived factors, including endothelin-1 (vasoconstrictor) 
and total nitric oxide (vasodilator), remained unchanged across both dietary interventions (Table 
3.3).  Due to the inability to attain blood from every participant during each visit, a few participants 




Table 3.1 Selected subject characteristics. 
Values are means±SEM.  There were no significant changes with either dietary condition. 
  
Variables No Dairy High Dairy 
Age (years) 58±2 58±2 
Height (cm) 169±1 169±1 
Body mass (kg) 85±2 85±2 
BMI (kg/m2) 29.3±0.8 29.2±0.8 
Heart rate (bpm) 61±1 62±1 
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Values are means±SEM. There were no significant changes. PWV=pulse wave velocity, FMD=flow-mediated dilation, Ep=Peterson 
elastic modulus, IMT=intima media thickness, BRS=baroreflex sensitivity. 
 No Dairy High Dairy 
Variables Before After Before After 
Ankle-brachial index 1.13±0.01 1.13±0.01 1.14±0.01 1.13±0.01 
Brachial-ankle PWV (m/sec) 14.9±0.3 14.6±0.3 14.9±0.3 14.5±0.3 
Carotid augmentation index (%) 23±2 23±2 24±2 21±2 
Baseline brachial artery diameter (mm) 3.97±0.10 4.00±0.10 4.00±0.10 3.98±0.10 
Peak brachial artery diameter (mm) 4.21±0.10 4.21±0.10 4.21±0.10 4.21±0.10 
Absolute FMD (mm) 0.25±0.02 0.21±0.02 0.23±0.02 0.21±0.02 
Carotid arterial compliance (mm2/mmHg x 10-1)  0.88±0.06 0.89±0.08 0.89±0.06 0.84±0.08 
Arterial distensibility (mmHg-1 x 10-3)  3.43±0.17 3.57±0.22 3.36±0.17 3.37±0.22 
β-stiffness index (U) 4.2±0.4 4.1±0.5 4.1±0.4 4.5±0.5 
Ep (mmHg)  697±34 692±42 679±34 728±42 
Carotid IMT (mm)  0.52±0.02 0.49±0.02 0.52±0.02 0.52±0.02 
Cardiovagal BRS (ms/mmHg)  8.3±0.8 9.5±0.7 9.5±0.8 8.2±0.7 
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Table 3.3 Changes in plasma concentrations of vasoactive factors with the dietary interventions. 
 





 No Dairy High Dairy 
Variables Before After Before After 
Endothelin-1 (pg/mL)  1.91±0.05 1.85±0.06 1.79±0.05 1.87±0.06 
Nitric oxide (µmol/L)  29.3±1.9 30.1±2.6 25.3±2.0 32.1±2.7 
Epinephrine (ng/mL) 21.9±5.3 25.5±4.0 30.4±5.3 28.4±4.0 
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Figure 3.2 Carotid-femoral pulse wave velocity (cfPWV) (A) and brachial artery flow-mediated 
dilation (FMD) (B) before and after no dairy and high dairy conditions.   





Figure 3.3 Main effect of time for carotid-femoral pulse wave velocity (cfPWV). *Denotes 






 The findings of the present study indicate that whole milk and full-fat dairy products added 
to the normal routine diet do not improve key vascular functions implicated in elevating BP.  
Specifically, the vascular stiffness measures implemented in the present study did not change 
during the dietary intervention.  No changes in endothelium-dependent vasodilation and 
cardiovagal baroreflex sensitivity were observed.  A lack of dietary effects on vascular function 
may be perceived as negative findings but may also suggest that saturated fat contained in whole 
milk and full-fat dairy do not impair vascular function.  The current investigation is the first dietary 
investigation study to determine the relationship between full-fat dairy products and arterial wall 
properties in adults with elevated BP. 
An increase in the stiffness of the large elastic arteries located in the cardiothoracic 
circulation is thought to be the primary mechanism underlying the age-associated increase in 
systolic BP.  In marked contrast to our previous investigation evaluating skim milk and non-fat 
dairy products [11], the present study utilizing the identical experimental protocol did not replicate 
the destiffening effects of dairy products as our whole milk and full-fat dairy products added to 
the normal routine diet did not induce changes in arterial stiffness.  To assess arterial wall 
properties as comprehensively as possible, we implemented a variety of methods in the present 
study.  Both propagation models (e.g., pulse wave velocity) and distention models (e.g., arterial 
compliance) consistently indicate that arterial stiffness did not change with either dietary 
intervention.  Our findings corroborate with the findings of previous studies indicating no 
detrimental effects of dairy products on central arterial stiffness [73, 83].  Given these findings 
over the short time span of the investigation (i.e. 4 weeks), it remains unknown whether longer-
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term full-fat dairy products might negatively impact the elastic mechanical properties of the arterial 
walls.   
Arterial baroreceptor-mediated changes in BP parallel changes in heart rate as a way to 
control BP on a beat-to-beat basis [84].  The sensitivity of these cardiovagal baroreceptors are 
blunted in adults with elevated blood pressure [85].  In our previous investigation, regular intake 
of skim milk and non-fat dairy products improved the sensitivity of the baroreceptors, and such 
changes were correlated to reductions in central arterial stiffness [10].  However, full-fat dairy 
products did not induce changes in BRS in the present investigation.  This finding may not be 
surprising given the lack of changes in arterial stiffness.  The compliance of carotid arteries and 
aorta in which arterial baroreceptors are located is closely associated with cardiovagal BRS 
through the ability of these reflexogenic regions to transduce signals [38].  
Reduced nitric oxide bioavailability appear to be responsible, at least in part, for the age-
associated augmentation in the vasoconstrictor tone of large conduit arteries [86].  Regular non- 
and low-fat dairy intake can produce significant improvements in endothelial function [9, 11].  
However, increased consumption of full-fat dairy products did not elicit similar improvements in 
endothelial function as estimated by FMD in the present study.  Follow-up analyses of plasma 
endothelium-dependent biomarkers NOx are consistent with the results in FMD.  Taken together, 
the regular consumption of whole milk and full-fat dairy products added to the normal routine diet 
does not appear to improve endothelial function in adults with elevated BP. 
Dairy micronutrients (e.g., potassium) and small peptides (e.g., lactotripeptides) contained 
in the milk and dairy products have been shown to have bioactive properties that affect vascular 
function [39, 40, 87].  Lactotripeptides (LTPs), formed from fermented dairy proteins, improve 
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endothelial function and central arterial compliance [39, 40] and also exert greater hypotensive 
effects with hypertensive than pre-hypertensive patients [88].  Mechanistically, LTPs have been 
shown to upregulate endothelial nitric oxide synthase in the aorta of spontaneously hypertensive 
rats [89].  Considering the fact that both non-fat and full-fat dairy products include these bioactive 
elements, what explains the discrepancy between non-fat and full-fat dairy products on the 
influence on vascular function?  We could only speculate on this but it is plausible that saturated 
fat in the full-fat dairy products may act to negate the beneficial effects of these bioactive 
compounds.  Indeed, protein consumption in combination with saturated fats eliminate the 
negative vascular effects attributable to the saturated fats [48, 90, 91].  Clearly, more research is 
necessary to investigate this mechanism.  
Even though we lack statistical power to properly conduct subgroup analyses, such 
analyses were undertaken.  However, they did not provide any new insight into the research 
findings.  Central arterial stiffness generally increases as a function of age [92], and arterial 
stiffening is known to reduce BRS as one advances in age [38].  Despite seeing no effects of sex, 
significant reductions in central arterial stiffness were seen among premenopausal females when 
compared with postmenopausal females.  Premenopausal females generally have reduced arterial 
stiffness than their postmenopausal counterparts as estrogen is responsible for maintaining 
elasticity of the arterial walls [93].  With respect to partial correlational analyses, it was surprising 
to show significant negative associations between BRS and increased whole milk and yogurt 




A lack of significant change in vascular function may be considered a negative finding 
with respect to dietary intake of whole milk and full-fat dairy products.  However, one may argue 
that no significant changes in vascular function may be perceived as a rather positive message 
given the negative ideology surrounding dairy fats and CVD risk.  Consistent with the present 
study, acute and longer-term effects elevating intakes of full-fat fermented and non-fermented 
dairy products have demonstrated no significant increases in pro- inflammatory, oxidative, or 
atherogenic biomarkers [94, 95].  Since an increasing number of investigators have recently begun 
to question the validity of the dietary recommendation to replace whole milk with reduced-fat 
milk, it may be clinically relevant to understand the interaction between isolated dairy elements 
and their impact on CVD risk.   
In summary, unlike nonfat dairy products demonstrating improvements in vascular 
function, whole milk and full-fat dairy products failed to improve vascular function in adults with 
elevated BP.  However, our findings also suggest that there are no negative effects involved in 
consuming full-fat dairy products on key vascular functions that are involved in the pathogenesis 
of CVD.  Based on our findings, four weeks of consuming full-fat dairy products do not contribute 
to vascular dysfunction.  Such knowledge is beneficial for future investigations examining the 
effects of long-term studies assessing full-fat dairy products for other therapeutic modalities.  
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Chapter 4: Review of Literature 
EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE 
Cardiovascular disease (CVD) is responsible for 1 in every 4 deaths, amounting to an 
annual death rate of 600,000 persons within the United States alone [96].  CVD is the leading cause 
of death not only within the United States [96] but on a global scale [63, 97], most notably within 
economically developed countries [98].  Despite these trends, CVD-related mortality has been 
declining over the past half-century worldwide [99, 100].  Such progress is not surprising as the 
decline in mortality can be attributed to more effective diagnoses, treatment, and accessibility to 
healthcare.  Developed countries are at the forefront of medicinal-based research affording 
therapeutic strategies to offset CVD risk.  The U.S. has taken a leadership role in educating the 
public about effective strategies to reduce the pronouncement of disease within a clinical setting 
[101-103].  Adopting such strategies through educational reform and governmental regulations 
toward reducing risk factors has effectively lowered prevalence and incidence of CVD-related 
mortality within other countries [104, 105].  Currently, lifestyle modifications are the first 
approaches to lower risks of cardiovascular disease [2].  Behavioral modifications are inexpensive 
and have the potential to improve cardiovascular health and to help counteract disproportionate 
factors and/or predispositions to CVD. 
Although a number of CVD risk factors can be reduced, several unmodifiable risk factors 
for progressing CVD exist: age, sex, race, and genetics.  Chronological aging is strongly associated 
with advanced stroke and heart disease risk [106, 107].  However, referencing chronological age 
as a risk factor for CVD does not adequately portray biological parameters of the arterial 
vasculature that is a more accurate and more precise determinant of CVD risk [108].    In younger 
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ages, males demonstrate a greater death rate from CVD than females [106], whereas the death rate 
attributed to females surpasses males after the fifth decade [63, 109] as estrogen is believed to 
confer vascular protection during pre-menopause [110]. However, estrogen therapy to lessen CVD 
risk [111] is controversial for postmenopausal women as estrogen supplementation has been linked 
to development of breast cancer [112].  Family history of CVD further increases the risk of CVD-
related events [113].  With respect to race, the Centers for Disease Control named CVD as the 
leading cause of death among non-Hispanic whites, non-Hispanic blacks, American Indians, and 
Alaskan Natives [96].  Although mortality rates from heart disease are similar among non-Hispanic 
whites and blacks, non-Hispanic blacks are more susceptible to stroke and diabetes [114].  A 
genetic predisposition may not entirely represent an underlying cause of CVD, as other 
disproportionate factors may play a role, particularly non-Hispanic blacks who have an overall 
lower socioeconomic status thereby limiting access to healthcare [115, 116].   
HYPERTENSION AS A RISK FACTOR FOR CVD 
Elevated BP is one of the leading risk factors for CVD-related mortality [23, 117] 
embodied as one of the many metrics to establish cardiovascular health [118].  Isolated systolic 
hypertension is the prevailing form of elevated BP when compared with systolic and diastolic 
hypertension or isolated diastolic hypertension [119].  Isolated systolic hypertension is accredited 
to consistently rising systolic BP with age and a concomitant reduction in diastolic BP after the 
fifth decade [22].  Furthermore, systolic BP is a greater predictor of CVD than diastolic BP [120].  
A systolic goal of <140 mmHg has been linked to lower CVD events and mortality risks [121-
123] and was a basis for the former cutoff value of stage I hypertension [1].  However, the most 
recent guidelines have established the cutoff for stage I hypertension as 130-139 mmHg in systolic 
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BP [124], which establishes the clinical relevance of controlling systolic BP to moderate CVD 
risk.  For the purpose of this review, preexisting guidelines established at the onset of this study 
will be utilized [1].   
Hypertension has been grouped into two etiological categories: primary and secondary 
hypertension.  Primary, or essential, hypertension exists when its origin remains unknown whereas 
a preceding event characterizes secondary, or incidental, hypertension.  Primary hypertension is 
often detectable in adolescents prior to being clinically diagnosed in young adulthood [125, 126].  
Due to the progressing nature of untreated hypertension with time [126], adolescents will carryover 
formerly developed CVD risk factors associated with elevated brachial systolic BP [127, 128] into 
adulthood.  Failure to diagnose a pronounced BP within children during the initial stages [129, 
130] counters the ability to recognize appropriate origins. Though the etiology of primary 
hypertension may not be attributed to a single known cause, excessive levels of sympathetic 
nervous system activity, salt intake, and genetics are suspected to be some of the principal factors 
[131-134].  Lifestyle modifications in the form of diet and exercise are a first line approach in the 
management of elevated BP [1, 2].  Inability to regulate primary hypertension will further damage 
vascular and organ tissue augmenting BP in what earlier investigators phrased ‘the vicious circle 
of hypertension’ [135], or chronic hypertension.  Sustained hypertension is a major contributable 
risk factor of hypertensive heart disease [4], a form of CVD resulting in left ventricular 
hypertrophy and eventual heart failure [136, 137].   
In the recent two decades, the hypertension-related death rate has been steadily increasing 
within the U.S., while all-cause mortality has been declining [138].  Susceptible groups of 
hypertensive-related mortality include women over the age of 85 years, Hispanics, non-Hispanic 
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whites, and non-Hispanic blacks; despite a reducing trend in non-Hispanic blacks that nevertheless 
demonstrate a majority cause of death associated with hypertension [138].   Additionally, 67% of 
adults over the age of 60 years have been diagnosed with hypertension [63], and 90% of the 
normotensive population at the age of 55 years is expected to develop hypertension at some point 
in their lifetime [1].  Hypertension is projected to heighten its incidence from 972 million in 2000 
to 1.56 billion in 2025, thereby increasing the global economic burden [139].   Every 20 or 10 
mmHg increase in systolic BP or diastolic BP, respectively, doubles CVD risk [1].  Reducing the 
level of hypertension is of paramount clinical importance in moderating CVD risk.   
LIFESTYLE MODIFICATIONS TO REDUCE HYPERTENSIVE RISK 
In 2010, a statement from the American Heart Association (AHA) issued a national goal 
to further reduce CVD mortality by 20% by the year 2020 [118].  To achieve this goal, a follow-
up study revealed a necessary shift in the population to meet “ideal cardiovascular health” 
qualifications, which appeared in approximately 0.1% of participants during the ARIC 
(Atherosclerosis Risk in Communities) study between 1987 and 1989 [140], demanding greater 
preventative efforts.  The seven metrics assessing cardiovascular health include health measures 
(total cholesterol, BP, blood sugar) and behavioral factors (nonsmoking, BMI, physical activity, 
healthy diet score).  A greater total number of ideal metrics corresponds to lower CVD risk [140].  
For this review, dieting strategies and BP will be mainly emphasized. 
The Mediterranean diet pattern was endorsed by the AHA, as part of the 2020 goals, to 
lower CVD risk – a dietary regimen rich in polyunsaturated fats, lean meats, and fiber-rich fruits, 
vegetables, nuts and whole-grains with diminished intake of saturated fats and sweetened 
beverages [118].  Although adherence to the Mediterranean diet is advantageous to reduce CVD-
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related mortality [141, 142], higher risk individuals are less likely to comply with such a dietary 
regimen [143, 144].  The U.S. is the lowest ranked country practicing such dietary habits [145].  
Yet, another study validated hypotensive effects of the DASH diet within the pre- and hypertensive 
community when compared against western and vegetarian diets [8].   Epidemiological studies 
have demonstrated associations with DASH dietary compliance and improved cardiovascular 
health [146].  The original DASH eating plan integrated fruits, vegetables, lean meats, whole-
grains, low-fat dairy and less intake of sweets and saturated fats, encompassing some similarities 
to the Mediterranean diet without elevated dietary fats.  Counseling patients within the primary 
care setting is a strong impetus for hypertensive patients to increase fruit, vegetable, low-fat dairy 
intake, and lower BP [147].  However, the effectiveness of reducing BP is limited when relying 
upon patient compliance opposed to clinical-based dietary provisions. 
Variations of the DASH diet incorporating reduced levels of sodium intake [148, 149] are 
equivalently effective as monotherapeutic antihypertensive medication [150, 151].  The reported 
mean intake of sodium within the U.S. in 2010 was estimated around 3.6 g/d and a global 
consumption of approximately 3.95 g/d [152] contributing to 1.65 million annual CVD-related 
deaths [153].   Excessive dietary sodium intake acts in a dose-dependent manner in raising systolic 
BP and portrays hypersensitivity among older, hypertensive, and general black communities [153].  
Individuals with sustained hypertension are affected more by a low-sodium DASH diet than those 
with lower BP levels [154].  Therefore, the AHA threshold for sodium consumption has been set 
to 1.5 g/d to lower BP within these sensitive groups and 2.3 g/d for unspecified groups [118] based 
on the DASH-sodium trial [148].  While there are multiple dietary sources containing sodium 
[155], roughly 77% has been attributed to processed foods [156] within the American diet.  
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Physiologically, abnormal kidney function, associated with advancing age and hypertension [157], 
causes inadequate processing of excessive sodium levels resulting in greater retention of water and 
subsequent volume overload heightening BP [132]. Consumption of unprocessed foods, 
ascertained by the low-sodium DASH eating plan [148], is appropriate and should be considered 
as a habitual practice among Americans’ eating habits. 
Aerobic exercise incorporated into a calorie-restricted DASH diet is also a practical 
approach in facilitating improved reductions of BP within an pre-, stage 1, and stage 2 hypertensive 
overweight population [71].  Body mass index (BMI), a surrogate measure of body fat, serves as 
a major cardiometabolic risk factor when classified as overweight [158, 159].  The AHA conceded 
to the BMI terms of the National Heart, Lung, and Blood Institute of 18.5-24.9 kg/m2 despite 
disease events occurring the least when the BMI range is 18.5-22 kg/m2 [118].  The prevalence of 
those meeting AHA’s BMI requirements within the U.S. has been steadily declining for adults and 
adolescents [63] indicative of a proportional increase of overweight individuals [160].  Overweight 
children are at greater risk of developing other comorbidities, including hypertension, diabetes, 
and cholesterol, during their adolescence than normal weight children [161] carrying over into 
their adult years [162].  Regular aerobic exercise has been identified to reduce body fat in 
overweight children [163] and adults [164] when compared to their sedentary counterparts.  
Moreover, cardiorespiratory fitness has been established to decrease hypertensive risk [165], even 
among adults who exercised regularly during their former upbringing and have diminished 
physical activity later in adulthood [166, 167].  Due to varying responses of aerobic exercising, 
calorie-restricted dieting is a more favorable strategy to reduce body weight [168, 169].  The 
macronutrient profile of any calorie-restricted diet can be modified to effectively lose weight [170] 
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even to target traditional risk factors attributable to CVD risk [169].  Combining calorie-restricted 
diets and exercise strategies exerts additive effects to lower CVD risk and body weight [71, 169].  
The efficacy of lifestyle modifications, through dieting and exercise to lessen CVD risk, has been 
advocated among several organizations [2, 5, 171].    
Manipulation of the macronutrient profile, or routine dietary foods without calorie 
restriction, also effectively reduces CVD risk.  The original DASH diet, rich in carbohydrates from 
natural sources [8], was responsible for cutting out refined sugars, which have been linked to 
hypertension [172, 173].  Multiple accommodative eating plans exist that similarly lower BP and 
CVD risk through enriched complex carbohydrate meals (i.e. DASH diet), or by partial 
replacement of carbohydrates with unsaturated fats (i.e. Mediterranean diet) or protein [49, 174].  
However, other dieting strategies manipulate regular eating habits by adding specific food items 
to the regular diet to determine health benefits maintaining isocaloric conditions. The original 
DASH trial popularized low- and non-fat dairy consumption but ineffectively segregated its 
hypotensive features from the rest of the diet [8].  Observational studies have since demonstrated 
inverse associations of low-fat dairy intake and BP [17, 175]. Furthermore, randomized clinical 
trials have attributed hypotensive effects to 3-4 daily servings of low- [9] or non-fat dairy products 
[10] to improve vascular function associated with elevated BP [11] when added to the normal 
routine diet opposed to a diet where dairy was absent.  Prior to these studies, the AHA cautiously 
refrained from including low-fat dairy as a dietary recommendation due to lacking causal evidence 





HYPOTENSIVE EFFECTS OF DAIRY CONSTITUENTS 
The heart-healthy properties arising from non- and low-fat dairy products has been ascribed 
to the dairy proteins.  The two major dairy proteins, casein and whey, compose 80% and 20% of 
total protein, respectively [177].   Compared to a normalized diet with varying protein sources, a 
three-month semi-isolated protein diet high in whey and casein, separately, revealed distinguishing 
elevations in glutathione, an antioxidant scavenger, within heart tissue of aged mice [178].  The 
effectiveness of whey protein to enhance intracellular glutathione is attributed to its enriched 
cysteine content [177], formerly identified as a rate-limiting substrate of glutathione synthesis 
[179].  Additionally, casein, rich in methionine [177], stimulates endogenous production of the 
intermediary byproduct homocysteine [180] before yielding cysteine and subsequent glutathione 
[44].  Excessive methionine intake [180], or reduced homocysteine flux, through deficient levels 
of choline [181], folate, B6 and B12 [182], are likely to result in hyperhomocysteinemia, an 
independent risk factor of CVD [183] responsible for oxidative damage [184] and vascular 
dysfunction [185].  Dairy products are a significant source of choline, folate, B6 and B12 [51] to 
negate the effects of copious levels of methionine alone.  The DASH diet revealed significant 
reductions in serum homocysteine levels when contrasted against a western and vegetarian diet 
[186].  Therefore, dairy proteins assist expanding the glutathione pool demonstrating antioxidative 
characteristics and protection against vascular dysfunction. 
Intriguingly, constituents of dairy proteins also accommodate antihypertensive and other 
advantageous vascular properties that lessen hypertensive risk. Casein-derived peptides, 
isoleucine-proline-proline and valine-proline-proline, or lactotripeptides, are the most common 
and potent peptides in dairy capable of reducing elevated systolic and diastolic BP [88, 187, 188].  
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Specifically, a LTP-based therapeutic intervention, analyzed against a placebo group, significantly 
lowered systolic BP, cardiac workload, and arterial vascular stiffening associated with CVD [189].  
Improvements in arterial stiffness and endothelial function corresponding to LTP ingestion is 
associated with parallel reductions in BP [39, 40].   Aside from LTPs, other nutraceutical features 
of dairy proteins include relaxation of vascular smooth muscle cells [190, 191], and suppression 
of vasoconstricting peptide hormones [192], vasoconstriction-responding receptors [193], and 
proinflammatory markers [194, 195] linked to early atherosclerotic plaque development [196].  
The capabilities of dairy protein supplementation to lower elevated BP while concomitantly 
promoting antioxidative status, should be regarded as an appropriate dieting strategy to modify 
CVD risk. 
Nevertheless, general saturated fat intake has been established as a cause of elevating 
systolic BP when compared to consuming unsaturated fatty acids [32, 33].  The mechanisms 
involving saturated fats contributing to elevated BP have been linked to reduced insulin sensitivity 
[60, 197] and increased oxidative stress promoting vascular dysfunction [198], increasing 
proinflammatory cytokines, and the RAS response that is associated with elevated BP [47, 48].  
Prolonging exposure of saturated fats within the circulation through reduced insulin sensitivity, 
especially among overweight and obese individuals, aggravates the renin angiotensin response 
through oxidative mechanisms [48].  Dietary proteins have been demonstrated to offset the 
oxidative effects to exert vascular protective effects [91, 199].  However, no study has yet 
demonstrated the degree to which dairy proteins may offset the hypertensive effects contributable 
to saturated fats found in dairy. 
 55 
 
Saturated fatty acids emanating from dairy sources are emerging as potential candidates 
for cardiovascular health.  In an abbreviated 3-week high-fat DASH trial [16], whole-fat dairy 
products were substituted in place of low- and non-fat dairy products and found to comparably 
lower BP as the original DASH eating plan.  However, data surrounding saturated fat in dairy has 
been mixed and inconclusive as observational studies have demonstrated inverse trends of BP and 
levels of whole-fat dairy consumption [15, 27, 175] or no relationship [17, 30].  The lack of 
sensitivity to detect hypotensive trends with whole-fat dairy intake may be limited from the 
blending of low- and whole-fat dairy consumers, often ingesting higher levels of low-fat dairy 
compared to whole-fat dairy [17, 30], or not accounting for distinctive dietary patterns linking low-
fat than whole-fat dairy consumers with healthier eating habits [17].   
However, saturated fats indicative of heart healthy benefits has challenged conventional 
thought in context of heart-healthy benefits.  Two saturated fats from dairy, pentadecanoate 
(C15:0) and transpalmitoleate (C16:1n-7) [200-202], endogenously produced in bovine milk, have 
demonstrated favorable BP effects despite a miniscule presence.  Self-reported data based on dairy 
fat intake revealed significant reductions in systolic and diastolic BP when compared from the 
lowest to highest quintiles of C15:0 and C16:1n-7 [203].  Other observational studies establishing 
associations in BP between low and high dairy fat intake have shown either no significant 
reductions in BP for C16:1n-7 [204], C15:0 [202], or positive findings for reduced BP with 
C16:1n-7 [205].  The previously mentioned studies finding no hypotensive trends [202, 204], also 
did not demonstrate hypertensive effects as other common saturated dairy fats such as myristic 
acid [203], stearic acid [32], or coconut oil rich in lauric acid [33].  Therefore, the effectiveness of 
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two fatty acids to lower BP may be limited in their ability to attenuate the hypertensive properties 
of alternative saturated fats identified in whole milk products.   
SATURATED FAT CONSUMPTION AND CVD RISK 
Conventional understanding of dietary saturated fat intake linked with CVD risk has been 
controversial.  Ancel Keys is identified for establishing the relationship between heart disease and 
overnutrition by total dietary fat and consequential elevation of total cholesterol [206, 207].  Early 
in Keys’ career, he discovered a strong association between dietary fat and CVD mortality, 
postulating evidence in support of a low-fat dietary regimen [208].  Some viewed Keys’ 
conclusions as valid [209] while others proved the study insufficient when held up to scrutiny 
[210].  Keys’ findings were simply dismissed based on several revelations: 1) weaker association 
when investigator bias was eliminated by including all countries opposed to a select few, 2) limited 
significance as the measure for total dietary fat intake was based on amounts available for 
consumption rather than what was actually consumed, and 3) lack of specificity as total protein 
available revealed similar relationships to CVD mortality in comparison to total fat [210].  Later, 
Keys’ differentiated between the hypo- and hypercholesterolemic effects of polyunsaturated and 
saturated fats, respectively [211, 212], establishing saturated fats from dairy and meat sources as 
the major contributors of total cholesterol and subsequent CVD risk [212].  Yet, extensive study 
of the cholesterol-lowering properties of polyunsaturated fat, particularly vegetable oils rich in 
linoleic acid [211, 213], has established no clear benefits to corresponding CVD risk [214, 215].  
Vascular consequences of excessive dietary linoleic acid intake may originate from a natural 
proclivity towards oxidized metabolites.  Oxidized linoleic acid derivatives have been established 
to be a major factor concerning oxidized LDL particles [216, 217] mechanistically releasing 
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proatherogenic compounds [218].  Given the little relevant scientific knowledge of dietary fats at 
the time, Keys was a significant figure to put the arguments forward despite surmising findings in 
a “blunt and cocksure manner [206].”  Ensuing debates that argued for greater scientific relevance 
prior to making presumptuous claims concerning saturated fats and CVD risk [219] were dismissed 
by Keys [220].  Despite debates among the scientific community, declining whole- and inclining 
low- and non-fat milk sales have spoken to the consensus among Americans since 1975 [221].  
Since the mid-2000’s, butter sales have also increased [222] as well as whole-fat milk in 2015-
2016 [221], suggesting a potential rise in dairy fat consumption. 
In 1977, the release of the first U.S. dietary guidelines endorsing a low-fat diet and 
replacement of fats for carbohydrates [223] has seemingly prompted additional health issues over 
time.  Since that time, diabetic and obesity prevalence accelerated [224, 225] along with ingestion 
of refined carbohydrates in place of complex carbohydrates [225].  Validation for such trends may 
be due to greater satiety levels following a meal with high saturated fat content than a 
carbohydrate-enriched meal [226] as endorsed by the 1977 guidelines.  Tradeoffs in the 
macronutrient profile of saturated fat for carbohydrates yields unfavorable health outcomes as 
refined sugars promote a greater CVD risk than saturated fats or carbohydrates from whole-grain 
products [35].  Furthermore, it has been well established that progression from the lowest to highest 
quintiles of saturated fat consumption, also among high-fat dairy consumption [227], is not 
associated with elevated CVD risk [20, 34, 35].  While the dining habits of Americans cannot be 
firmly ascribed to the 1977 guidelines, saturated fat may not be the exclusive culprit responsible 
for elevated CVD risk. 
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The integration of certain dietary habits through incorporation of heart-healthy foods may 
be the key to further offset potential CVD risk when consuming saturated fat.  Two European 
countries, Finland and France, are infamous consumers of saturated fat being among the highest 
worldwide [228].  Yet, despite similarly elevated cholesterol [229] and BP levels [229, 230], 
France has the lowest CVD mortality risk than any other country [228], formerly identified as the 
“French paradox”.  Several dietary trends may explain the existence of the French paradox 
including daily moderate wine consumption to prevent platelet aggregation [229, 231], high 
consumption of vegetable and whole food items [228], and small portion sizes [232].  In contrast, 
the Finnish had a dietary regimen rich in saturated fat, protein, carbohydrates [228, 233], and 
sodium [104] with little vegetable and fruit sources.  Since the late 1970s, CVD risk has been 
reduced among the Finnish [234] when it was first identified by Keys as a high risk country [235].  
Although high dairy fat consumption is associated with greater CVD risk among the Finnish [228], 
the French have lower risk undeterred by similar levels of dairy fat intake as other developed 
countries [229].  Therefore, all contributable dietary CVD risk factors should be assessed with 
their complementary or uncomplimentary roles in conjunction with saturated fat.  
Results from studies revealing that saturated fats have minimal cardiovascular consequence 
[20, 34, 35], and reduced prevalence of hypertension in populations consuming high amounts of 
whole-fat dairy products [15, 27, 175], has many advocates jumping onto the “butter is back!” 
campaign.  However, current understanding is still very limited, and navigation of potential health 
implications is ongoing.  Due to LDL cholesterol being a major CVD risk factor, <7% of total 
energy provided by saturated fats are recommended by the AHA based on previous literature 
linking saturated fats to increased cholesterol levels [118].  The negative hypercholesterolemic 
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effects of saturated fat consumption are offset by increasing HDL cholesterol levels [36].  
Partitioning saturated fatty acids according to chain length also has varying effects on cholesterol.  
Specifically, shorter fatty acids markedly raise LDL and HDL cholesterol levels to a greater degree 
than longer saturated fatty acids [36, 236].  Palmitic acid (16:0), which constitutes the highest 
concentration of saturated fats in dairy [51], has demonstrated hypocholesterolemic properties in 
men and women with normal cholesterol levels [237, 238].  Moreover, the 
thromboxane/prostacyclin ratio, respectively platelet aggregate promoter/platelet aggregate 
inhibitor ratio [239, 240], was demonstrated to be quite favorable in participants consuming 
palmitic-rich oils in comparison to coconut or olive oils [237].  The singular effects of other major 
saturated fatty acids found in dairy, differentially affect cholesterol levels by respectively exerting 
no effects or decreases in LDL and HDL cholesterol with stearic acid supplementation (18:0) [241] 
and increases in both LDL and HDL cholesterol with myristic supplementation (14:0) [242] when 
compared to baseline in healthy participants.  Additional nutrients in particular foods may also 
play a role in reducing cholesterol levels such as dairy calcium reducing absorption of fats in the 
gut associated with lowered LDL serum cholesterol levels when analyzed against a controlled 
isocaloric diet [243].  Thus, the contrasting hyper- and hypocholesterolemic effects of solitary 
saturated fatty acids, among other nutrients, could potentially counterbalance the heart health 
paradigm. 
Overall, the cardiovascular benefits associated with whole-fat dairy product consumption 
seem optimistic.  However, a lack of causal evidence remains to determine the efficacy of whole-
fat dairy on adults with elevated BP.  The high-fat DASH trial, which substituted non- and low-fat 
for whole-fat dairy products, effectively demonstrated a similar hypotensive response to the 
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normal DASH eating plan [16].  From these results, it could be argued that a reduction in BP was 
the result of a holistic nutritive approach that incorporated whole foods to increase ingestion of 
complex carbs, vegetables, and fruits apart from the normalized eating patterns of western 
civilization.  Therefore, to assess the potential hypotensive properties of whole-fat dairy, studies 
that provide additional whole-fat dairy products to the normal routine diet are necessary.   
VASCULAR FUNCTIONS ASSOCIATED WITH AGING, HYPERTENSION, AND DAIRY CONSUMPTION 
BP is the measure of circumferential force exerted on the arterial wall perpendicular to 
blood flow.  Under pulsatile conditions, the corresponding distension and recoil properties of the 
arteries, from the respective aftereffects of contraction (systole) and relaxation (diastole) of the 
myocardium [244], responsible for controlling the conductance of blood, diminish with advancing 
age.  The distension of the arterial wall acts as a buffer to the systolic pressure by storing blood to 
be later released during recoil, or diastole, also known as the Windkessel model [245].  Sustained 
forces from chronic hypertension cause eventual fatigue the elastic components of the arterial wall 
[246], a property of the central arterial elastic arteries [77], leading to enhanced collagen synthesis 
and overall arterial stiffness [247-249].  Aside from fatiguing elastic lamellae of the arterial wall, 
elevated cholesterol bolsters arterial stiffness through plaque calcification [250].  Yet, arterial 
stiffness and elevated BP can be lowered through cholesterol reduction  [251].  Arterial stiffness 
is an independent predictor of CVD mortality [12], particularly among the hypertensive population 
[252].  Inherent arterial stiffening is also subsequently associated with incidental systolic 
hypertensive risk [66], demonstrating the potential elastic properties of the arterial wall to affect 
BP.  Advancing age is also directly associated with rising BP and arterial stiffness [92, 253, 254].  
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Therefore, therapeutic intervention trials aimed at reducing hypertension may inadvertently reduce 
arterial stiffness.   
The endothelium is the innermost lining of the arterial wall and serves as the first-line 
defense against atherogenesis [110].  Responsible for the balance between vasoconstriction and 
vasodilation, the simple squamous layer of cells produce nitric oxide  (NO) [255], a potent 
vasodilator, and endothelin-1 (ET-1) [256, 257], a powerful vasoconstrictor.  Due to their 
proximity of the lumen, endothelial cells are primary targets for cellular destruction from reactive 
oxygen species and inflammatory markers [258-260].  Studies have validated endothelial 
dysfunction progressing with arterial stiffness [67, 68] and arterial stiffness promoting endothelial 
dysfunction [261].  Therefore, maintaining arterial elasticity is important for endothelial function 
despite origins of pathology.  Additional initiating factors contributing to endothelial dysfunction 
has been linked to hypertension, atherosclerosis, thrombus development, and myocardial 
infarctions from plaque buildup in the coronary arteries [110, 258, 259, 262].  Patients with 
apparent CVD risk factors exhibit reduced blood flow in comparison with healthy individuals 
[263].  Blood flow is important for arterial vasomotor activity [264], particularly in the production 
of endothelium-dependent NO [265, 266] to inhibit ET-1 production and subsequent platelet 
aggregation [267, 268].  Therefore, reductions in blood flow are significantly associated with 
CVD-related events compared to those with adequate blood flow [260]. Clinical research has 
demonstrated reversal of hypertensive-associated endothelial dysfunction through 
antihypertensive treatments [269], suggesting the importance of regulating elevated BP to 
modulate endothelial function.  Age-associated endothelial dysfunction naturally decreases to a 
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similar magnitude for normo- and hypertensive individuals [270, 271], but a greater degree of 
impairment is visible with the aging hypertensive population [270].   
Together, endothelial dysfunction, arterial stiffness, and hypertension are factors that blunt 
baroreceptor sensitivity (BRS).  With nerve endings located within the medial layer of the carotid 
arteries and aorta [272], baroreceptors are sensitive to excessive distension of the arterial wall from 
short-term elevated systolic BP [132].  The baroreceptors mediate sympathetic output regulating 
vessel diameter [273].  Sustained hypertension results in a heightened operational threshold of the 
baroreceptors [132] resulting in reduced function of the baroreceptors [85].  Moreover, arterial 
stiffening is an independent risk factor of impaired BRS [274], limiting the functional capacity of 
the baroreceptors by reducing afferent inputs [275].  In animal models, prostaglandins released 
from endothelial cells stimulate baroreceptors during episodic hypertension to promote 
vasodilation in a paracrine manner [276, 277].  Thus, endothelial dysfunction results in less 
prostaglandins released contributing to an impaired BRS, especially in animal models with chronic 
hypertension [277, 278].  Based on these functional components of BRS, impairment has been 
classified as a strong prognostic indicator of CVD-related mortality [279]. 
Dietary intervention strategies have been used to improve vascular function and overall 
CVD risk.  Aimed at reducing elevated BP, clinical trials have also demonstrated favorable effects 
toward vascular functional parameters.  The original DASH eating plan validated the effectiveness 
of the diet to improve central arterial stiffness [71] and endothelial function [71, 280] in contrast 
to those consuming a typical western diet.  Moreover, addition of non-fat dairy products to the 
normal routine diet improved central arterial stiffness, endothelial function, and BRS while 
concomitantly reducing elevated BP when compared to an isocaloric control [11].  Despite positive 
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findings surrounding non-fat dairy consumption, the controversial data surrounding whole-fat 
dairy product consumption has not been thoroughly examined.  To date, observational studies have 
provided mixed results concerning whole-fat dairy consumption by demonstrating increased 
central arterial stiffness compared to no consumption [74], or no effect when examined across the 
lowest and highest quartiles [83].  Aside from observational studies, no clinical investigations have 
yet assessed the efficacy of whole-fat dairy intake on the vascular function profile.  
NERVOUS SYSTEM INVOLVEMENT IN HYPERTENSION 
Excessive sympathetic nervous system activity has been demonstrated to be directly related 
to advancing age [281-283] and hypertension [284], contributing to the increased essential 
hypertension with aging.  Furthermore, blunted sensitivity to inhibitory sympatholytic drugs 
within the aged [285], represents a predicament that the geriatric population faces in overpowering 
such sympathetic outflow [286]. Systemically, elevated whole blood norepinephrine 
concentrations, from sympathetic neuronal spillover or low reuptake [286, 287], activates 
downstream α-adrenergic receptors to intensify vasoconstrictor tone and subsequent BP.  The 
ability to modify arterial stiffness is believed to be partly due to the contractile state of 
vasoconstrictor tone exerted by the smooth muscle cells in the arterial wall [288-290].  Therefore, 
suppression of vascular tone, via augmented NO bioavailability, is likely to reduce arterial 
stiffening in hypertensive individuals by promoting elasticity [291, 292].  Other factors including 
weight gain [293] and saturated fat intake [48] are also associated with increased sympathetic 
activity further contributing to an elevated BP response. 
Systemic sympathetic nervous system activity is modulated through the central nervous 
system.  Baroreceptors are the primary mediators relaying elevated BP to central command, 
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dampening sudden rises through a feedback loop mechanism within the central nervous system 
[132, 294].  Episodic elevations in BP exceeding the set point of the baroreceptors generates 
afferent sympathetic signals to the nucleus tractus solitaries (NTS).  From the NTS, the neuronal 
tracts bifurcate into the parasympathetic branch of the heart to reduce cardiac output [273] and 
inhibitory interneurons within the caudal ventrolateral medulla [295].  In turn, the caudal 
ventrolateral medulla exerts inhibitory effects on tonically-active neurons within the rostral 
ventrolateral medulla (RVLM) inducing reduced arterial vasoconstrictor tone [296].  Majority of 
neurons within the RVLM are glutamatergic and synthesize adrenaline thereby continuously 
evoking sympathetic efferent signals when uninhibited [297, 298].  The RVLM also selectively 
facilitates the production of norepinephrine from neuroendocrine cells located within the adrenal 
medulla.  Unlike epinephrine adrenal preganglionic neurons that are insensitive to the baroreflex, 
the norepinephrine neurons are inhibited upon the BRS reflex [299].  At rest, sympathetic signals 
arising from the RVLM are unlikely to raise BP unless other sympathoexcitatory stressors are 
present.   
The central nervous system is also responsible for regulation of blood volume regulation 
through the kidneys.  The paraventricular nucleus of the hypothalamus, responsible for detecting 
increases in blood osmolality from water deprivation, contains sympathetic afferent projections to 
the RVLM [300, 301].  The RVLM then sends efferent inputs to the kidney glands promoting renin 
production to preserve BP to end-target organs from blood volume loss [302, 303], initiating RAS.  
Renin activates angiotensinogen to advance AngII production [304, 305] stimulating the release 
of aldosterone from the adrenal glands to reuptake sodium and induce arterial vasoconstriction to 
maintain blood perfusion to end-target organs [306].  In turn, circulating AngII elevates 
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sympathetic efferents arising from the RVLM [307] and is appropriately regarded as a sympathetic 
modulator of BP.  Moreover, AngII has exhibited pressure-independent resetting of carotid 
baroceptor regulation of mean arterial BP and heart rate [308].  Therefore, AngII blunts 
baroreceptor sensitivity to detect changes in BP thereby exerting central pressor effects.  AngII 
release can propagate other issues such as suppressing production of NO by obstructing the uptake 
of its precursor into the endothelial cells [89, 309].   Additionally, AngII fosters collagen synthesis 
[89] and inflammation associated with atherosclerotic lesion development [310, 311] and 
successive arterial stiffness.  Angiotensin converting enzyme (ACE), responsible for converting 
AngI to AngII, has been viewed as an essential component of AngII-induced hypertension and 
targeted for inhibition as a strategy to lower hypertensive and CVD risk [89, 312].   
Antihypertensive casein-derived proteins found in dairy products contain ACE inhibiting 
properties, known as LTPs.  Despite a multitude of ACE inhibitory-like proteins found in dairy 
[313-315], the most common and potent lactotripeptides are isoleucine-proline-proline and valine-
proline-proline [88].  Long-term pharmaceutical ACE inhibitors have demonstrated similar 
properties in comparison to vasodilators [316] reducing BP, vascular resistance, intima media 
thickness, and left ventricular hypertrophy [317].  LTPs were among the first biopeptides to 
enlighten the scientific community regarding health implications from diminished BP [187].  In 
vitro analyses have validated that LTPs are advantageous toward increasing NO levels to reduce 
vasoconstrictor tone [89, 318].  With respect to sympathetic neuronal activity, a 12-week 
hypocaloric DASH trial demonstrated significantly reduced sympathetic nerve activity among 
hypertensive individuals and reduced norepinephrine levels compared to baseline [319].  Yet, the 
participants also demonstrated 12-week weight loss, which has also been associated to reduced 
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sympathetic nerve activity, reduced norepinephrine, and restored baroreflex function [320].  Full-
fat dairy products have not been thoroughly examined with respect to sympathetic nerve activity.  
It would be reasonable to assume that increased whole-fat dairy would elicit similar effects to LTP-
isolated nutraceuticals or low-fat dairy intake as they contain similar hypotensive constituents.  
However, previous studies have established a compromised norepinephrine uptake [321] and 
release [322] impairing storage and release in rats.  A diet high in saturated fat has been shown to 
increase oxidation to diminish endothelial function and subsequent NO production [323].  As 
oxidation increases AngII production, saturated fat most likely contributes to arterial smooth 
muscle tone to elevate BP. 
BLOOD PRESSURE MEASURES 
Accurate methodology surrounding BP measurements is of imperative importance when 
assessing CVD risk to avoid false readings.  Despite mercury sphygmomanometers being 
identified as the gold standard for BP determination, automated devices have increased in 
popularity within the clinical setting [41].  Automated devices have been shown to provide similar 
accuracy to mercury sphygmomanometers [324, 325] while limiting inter-individual variability.  
Due to the ease of use, home-based measurements by the patient are highly encouraged to avoid 
false readings associated with white coat hypertension [124].  Seated BP measurements are 
notorious for misdiagnosing hypertension by providing false readings due to patient anxiety, 
known as “white coat hypertension”, which occurs among 20-40% of patients [326-328].  
Physicians are more likely to trigger alarm in patients than nurses during office visits, especially 
within the geriatric population [329]. Home and 24-hour ambulatory BP monitoring are better 
prognostic indicators of CVD risk than office-based measurements [41, 330-332].   
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Precision and accuracy are not the only benefits to wearing a 24-hour ambulatory BP 
monitor, as other CVD risk factors may also be detected.  Generally, the circadian rhythms cause 
BP to steadily rise from early morning hours and remain elevated until late afternoon when BP 
starts to fall and dips while sleeping [333].  Dipping patterns in BP are important when considering 
CVD risk as higher CVD-related events and mortality have been linked to non-dipping individuals 
[334], which is more typical among non-Hispanic blacks than whites [335].  Patients with dipping 
BP are more likely to experience a sudden increase upon awakening, known as the “morning 
surge” [336],  which is associated with higher CVD risk than those whose rise is slower and more 
steady [333, 337].  Comparatively, it is unknown whether morning surgers or non-dipping 
individuals are at a greater CVD risk, but therapeutic interventions can reverse non-dippers into 
dippers to help eliminate morning surge, especially when hypertensive medication is taken upon 
awakening [333, 334].  Hormonal regulators follow circadian BP patterns such as plasma 
norepinephrine has been linked to postural changes that occur upon awakening [338, 339].  The 




Chapter 5: Summary and Future Directions 
SUMMARY 
Lifestyle modifications in the form of diet are the first line approach to manage elevated 
BP [25].  A diet high in dairy intake, especially non- and low-fat dairy products, have been 
demonstrated to lessen hypertension risk [8-10].  However, the effects of whole milk and full-fat 
dairy intake on blood pressure were unknown from an interventional perspective. 
The DASH eating plan is a widely recommended dietary approach to reduce elevated blood 
pressure [8].  The DASH study demonstrated that a combined diet of fruits and vegetables with 
low-fat dairy products resulted in a greater magnitude of BP reduction than a diet rich in fruits and 
vegetables.  Based on such results, we conducted a randomized controlled dietary intervention trial 
adding skim milk and non-fat dairy products to the normal routine diet of adults with elevated 
blood pressure [10].  Subjects reduced blood pressure by solitarily adding 4 daily servings of dairy 
for 4 weeks.  Further, the effects of skim milk and non-fat dairy products also improved vascular 
function by reducing central arterial stiffening, improving endothelial function, and increasing 
baroreceptor sensitivity [11].  The results from that previous investigation are consistent with the 
findings from observational studies [17, 175] demonstrating the effectiveness of non-fat dairy to 
reduce BP in adults with elevated BP. 
A modified higher-fat DASH diet incorporating full-fat dairy products in place of non- and 
low-fat dairy products from the original DASH diet [16], reduced blood pressure to a similar 
degree as the original DASH.  Among observational cohort studies, there are mixed and 
inconclusive results demonstrating no reductions in BP [29, 30] to some showing significant 
reductions in blood pressure with higher intake of full-fat dairy [15, 27].  To determine the causal 
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implications of full-fat dairy, we performed a randomized controlled dietary intervention study to 
assess the effects of whole milk and full-fat dairy products on adults with elevated BP.  The results 
from the current dissertational study did not demonstrate a hypotensive trend through the solitary 
addition of 4 daily servings of full-fat dairy for 4 weeks.  In addition, there were no improvements 
in central arterial stiffness, endothelial function, or cardiovagal baroreceptor sensitivity.   
Based on these findings, the solitary addition of whole milk and full-fat dairy consumption 
are not consistent with the previous investigations showing the hypotensive impacts of skim milk 
and non-fat dairy in adults with elevated blood pressure.  Therefore, adding full-dairy products to 
the normal routine diet is not a recommended approach to reduce BP in adults with elevated BP.   
FUTURE DIRECTIONS 
The research design of the current dissertational project was chosen given the success of 
our previous investigation of non-fat dairy products eliciting hypotensive effects [10, 11].  
However, our current understanding of the isolated interaction between dairy fat and protein are 
still not understood.  Previous investigations have noted acute postprandial effects of saturated fats 
to increase RAS, proinflammatory markers, and oxidative species to promote endothelial 
dysfunction [48, 60, 198].  When proteins are added to a meal rich in saturated fat, the effects of 
endothelial dysfunction from elevated saturated intake are ameliorated [91, 199].  Based on the 
limitation of the current investigations to isolate the effects of the various dairy constituents, 
mechanistic factors attributable to various dairy constituents could not be examined.  Future 
investigations should study the mechanistic effects of acute postprandial effects of isolated dairy 
fat and protein in adults with elevated blood pressure.  Such investigations would aid further 
understanding concerning how saturated fat interferes with the hypotensive properties of dairy.  
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Given the negative attributes of saturated fat on the blood pressure and the vasculature, it is also 
of interest to understand if lowering the saturated fat content of dairy through incorporation of both 
low- and full-fat dairy products to the normal routine diet exert hypotensive effects and 









Appendix A: Abbreviations and Acronyms 
ACE = angiotensin converting enzyme 
Ang = angiotensin  
ANOVA = analysis of variance 
BMI = body mass index 
BP = blood pressure 
BRS = baroreflex sensitivity 
cfPWV = carotid-femoral pulse wave velocity 
CVD = cardiovascular disease 
DASH = dietary approaches to stop hypertension 
ET-1 = endothelin-1 
FMD = flow-mediated dilation 
HbA1c = glycated hemoglobin 
HDL = high density lipoprotein 
JNC = Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure 
LDL = low density lipoprotein 
LTP = lactotripeptide 
NO = nitric oxide 
RAS = renin angiotensin system 





















Appendix C: Daily Dietary Surveys 
Dairy Study Week # 
________ 
         
Subject 
ID_______________________________ 
                      
 Date  study food picked 
up:_________________ 
Consume 4 provided dairy servings per day                                  Check 
items off list as consumed each day 
Dairy items 
# servings 
issued Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
8 oz. whole milk ______ 
              
              
              
              
8 oz. full-fat yogurt ______ 
              
              
              
              
1.5 slices Swiss cheese 
______ 
                                          
                                          
                                            
                                          
  
                     
List below any additional dairy products consumed that were not provided by laboratory 
  
                     
Non-Laboratory Provided Dairy items Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
                
                
                
                
                
                  
  
                     
  
                     
  
                     






Dairy Study Week # 
________ 
         
Subject 
ID_______________________________ 
                      
 Date study food picked 
up:_________________ 
Consume 4 provided fruit servings per day                                   Check 
items off list as consumed each day 
Fruit items 
# servings 
issued Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
8 oz. Coconut Milk ______ 
              
              
              
              
8 oz. Orange Juice ______ 
              
              
              
              
Peanuts or Sunflower 
Seeds 
______ 
              
              
Fruit Cup 
              
              
  
                     
List below any fruit/fruit juice consumed that was not provided by laboratory  
  
                     
Non-Laboratory Provided Fruit items Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
                
                
                
                
                
                  
  
                                                                   




Appendix D: Three-Day Dietary Record 
 
3-Day Food Intake Record Instructions 
 
1. Record day of the week and date for everything you eat and drink for three days (two week 
days & one weekend day) prior to arriving at your appointment.   
2. Include the time, amount and type of food/beverage consumed. Provide as much detail as 
possible, including brand names when available. For example, instead of recording “cereal 
with milk”, record “1.5 cups Kashi GoLean cereal with 6 oz low-fat milk”. Instead of “1 
slice wheat toast with jam”, record “1 slice Orowheat 100% whole-wheat toast with 1tsp 
Smucker’s low-sugar strawberry preserves”. See sample food log for more examples.  
3. For combination foods such as chili, soup, casseroles, sandwiches, list all items in the food 
and amounts of each item.   
4. For dairy products (milk, cheese, yogurt, etc) record whether, regular (whole), lowfat (1%), 
reduced fat (2%), or nonfat (skim).  
5. Include sweeteners (sugar, honey, syrup, etc) and fats (cream, half&half, milk, etc) added 
to coffee, tea, etc; as well as spreads on breads and dressings on salads.  













Amount Brand Food/Beverage 
  8am 8 oz  Nonfat milk (in cereal) 
 12 oz  Black coffee 
 1 Tsp  Sugar in coffee 
 1.5 Cups Nature’s Path Heritage Heirloom Whole Grains Cereal 
 1 T Sun-Maid Fruit bits 
 1 medium  Cara Cara navel orange 
12pm 
1.3  Cups Homemade Chili: ½ Cup 70% lean ground beef, 1 T onion, 2 T 
garbanzo beans, 2T black beans, 2 T red sweet 
pepper 
 3 T  Grated cheddar/jack cheese, regular 
 ½ Cup  Fresh strawberries 
 ½ Cup Stoneyfield Lowfat vanilla yogurt 
 2 T  Raw almonds 
3pm 1 Cliff Chocolate Builder’s Bar 
6pm 5 oz  Grilled chicken breast, skinless 
 
¾ Cup  Slaw:  ¼ cup cabbage, ¼ grated carrots, ¼ 
broccoli, 1 tsp olive oil, 1 tsp cider vinegar 
 
1 piece Kirkland 
Signature 
Multigrain bread 
 2 tsp  honey 
 ½ tsp  butter 
 
¾ Cup  Grilled vegetables:  ¼ cup yellow squash, ¼ red 








Amount Brand Food / Beverage 
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Appendix E: Supplemental Data 
Table E.1 Changes in select subject characteristics and blood chemistry. 
  No Dairy Condition First (n=30) High Dairy Condition First (n=30) 
  No Dairy High Dairy High Dairy No Dairy 
Variables Before After Before After Before After Before After 
Height (cm) 168±2 - 168±2 - 170±2 - 170±2 - 
Body mass (kg) 85.7±3.6 86.3±3.5 86.4±3.6 86.9±3.5 82.9±3.5 83.3±3.4 83.5±3.5 83.7±3.4 
BMI (kg/m2) 30.3±1.1 30.5±1.1 30.5±1.1 30.6±1.1 28.8±1.1 29.1±1.1 29.2±1.1 29.3±1.1 
Total cholesterol (mmol/L) 5.2±0.2 5.1±0.2 5.1±0.2 5.4±0.2 5.0±0.2 5.0±0.2 5.0±0.2 4.9±0.2 
HDL cholesterol (mmol/L) 1.4±0.1 1.3±0.1 1.3±0.1 1.4±0.1 1.3±0.1 1.3±0.1 1.3±0.1 1.2±0.1 
LDL cholesterol (mmol/L) 3.1±0.2 3.0±0.2 3.1±0.2 3.4±0.2 3.0±0.2 3.2±0.2 3.0±0.2 3.1±0.2 
Triglycerides (mmol/L) 1.5±0.2 1.5±0.2 1.3±0.3 1.5±0.2 1.5±0.2 1.5±0.2 1.6±0.3 1.3±0.3 
Blood glucose (mmol/L) 5.3±0.1 5.3±0.1 5.2±0.1 5.5±0.1 5.3±0.1 5.5±0.1 5.3±0.1 5.2±0.1 
Glycated hemoglobin (%) 5.6±0.1 5.6±0.1 5.6±0.1 5.6±0.1 5.5±0.1 5.6±0.1 5.6±0.1 5.6±0.1 
Insulin (pmol/L) 66.5±9.5 63.3±6.4 68.6±7.8 65.8±6.1 64.9±6.1 66.6±6.4 64.7±7.6 63.4±6.0 
Systolic BP (mmHg) 139±2 130±2 135±2 133±2 136±2 132±2 134±2 135±2 
Diastolic BP (mmHg) 81±2 79±2 81±2 80±2 85±2 84±2 84±2 85±2 




Table E.2 Changes in dietary composition. 
Values are means±SEM. 
  
  No Dairy Condition First (n=30) High Dairy Condition First (n=30) 
  No Dairy High Dairy High Dairy No Dairy 
Variables Before After Before After Before After Before After 
Calories (kcal/d) 2086±97 1986±93 1968±97 2103±104 1960±95 2081±89 1899±96 2023±103 
Total_Fat (g/d) 88±5 91±4 89±5 98±5 81±5 94±4 79±5 88±5 
Sat_Fat (g/d) 28±2 30±2 27±2 40±2 27±2 38±2 27±2 27±2 
Monounsat (g/d) 21±2 25±1 21±2 20±1 20±2 20±1 19±2 24±1 
Polyunsat (g/d) 12±1 10±1 12±1 11±1 10±1 10±1 10±1 9±1 
Total_CHO (g/d) 239±15 234±11 229±14 205±13 216±14 216±10 210±14 237±13 
Total Fiber (g/d) 20±2 21±1 19±1 17±1 19±2 17±1 18±1 20±1 
Total_Sugar (g/d) 99±8 114±8 89±8 83±7 82±8 86±7 81±8 110±6 
Total_Pro (g/d) 82±5 72±7 78±4 92±5 77±5 96±5 73±4 74±5 
Alcohol (g/d) 7±3 5±2 4±2 4±2 4±3 3±2 5±2 2±2 
Sodium (mg/d) 3052±205 2326±205 3010±226 2692±272 3188±201 2929±196 3009±223 2968±269 
Potassium (mg/d) 2147±166 2602±161 2072±144 2284±142 1965±163 2232±154 1769±142 2733±140 
Calcium (mg/d) 818±75 2083±179 786±86 1530±79 866±74 1412±170 994±85 1894±79 
Magnesium (mg/d) 218±20 200±21 219±19 209±19 201±19 219±20 202±19 217±18 
Vit_D (IU/d) 470±202 796±207 424±193 496±164 537±196 608±200 514±188 591±161 
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Table E.3 Changes in blood pressure for blood pressure medication users and non-users. 
  No Dairy High Dairy 
Variables Before After Before After 
Antihypertensive Drugs (n=23)         
Systolic BP (mmHg) 137±2 132±2 138±2 135±2 
Diastolic BP (mmHg) 82±3 80±2 83±2 83±2 
No Drugs (n=37)         
Systolic BP (mmHg) 136±2 134±2 134±2 131±2 
Diastolic BP (mmHg) 83±2 83±2 83±2 81±2 
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